

REVIEW ARTICLE

Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks

Brian MAGNUSON*¹, Bilgen EKIM*¹ and Diane C. FINGAR*^{†2}

*Department of Cell and Developmental Biology, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, U.S.A., and †Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, U.S.A.

The ribosomal protein S6K (S6 kinase) represents an extensively studied effector of the TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely defined roles in cellular and organismal physiology. TORC1 functions as an environmental sensor by integrating signals derived from diverse environmental cues to promote anabolic and inhibit catabolic cellular functions. mTORC1 (mammalian TORC1) phosphorylates and activates S6K1 and S6K2, whose first identified substrate was rpS6 (ribosomal protein S6), a component of the 40S ribosome. Studies over the past decade have uncovered a number of additional S6K1 substrates, revealing multiple levels at which the mTORC1–S6K1 axis regulates cell physiology. The results thus far indicate that the mTORC1–S6K1 axis controls fundamental cellular processes, including transcription, translation, protein and lipid synthesis, cell growth/size and cell metabolism. In the present review we summarize the regulation of

S6Ks, their cellular substrates and functions, and their integration within rapidly expanding mTOR (mammalian TOR) signalling networks. Although our understanding of the role of mTORC1–S6K1 signalling in physiology remains in its infancy, evidence indicates that this signalling axis controls, at least in part, glucose homeostasis, insulin sensitivity, adipocyte metabolism, body mass and energy balance, tissue and organ size, learning, memory and aging. As dysregulation of this signalling axis contributes to diverse disease states, improved understanding of S6K regulation and function within mTOR signalling networks may enable the development of novel therapeutics.

Key words: mammalian target of rapamycin complex 1 (mTORC1), mammalian target of rapamycin complex 2 (mTORC2), S6 kinase 1 (S6K1), S6 kinase 2 (S6K2), target of rapamycin (TOR).

INTRODUCTION

Organismal homeostasis requires that cells, tissues and organs respond appropriately to diverse environmental cues, which operate via tightly controlled signal transduction networks. Indeed, the dysregulation of many signalling pathways underlies numerous human pathological disease states. The protein kinase TOR (target of rapamycin) functions as an evolutionarily conserved environmental sensor. In unicellular eukaryotes, such as yeasts, TOR responds primarily to nutrient levels. Evolution of multicellular organisms provided TOR with the ability to respond to a diverse array of environmental cues, such as hormones, growth factors and mitogens, enabling this kinase to orchestrate a myriad of cellular functions. From yeasts to mammals, TOR

forms at least two multi-protein complexes known as TORC1 (TOR complex 1) and TORC2 [1–3]. These complexes exhibit distinct subunit composition, regulation, substrate selectivity and sensitivity to the drug inhibitor rapamycin, clinically known as sirolimus. TORC1, which displays sensitivity to acute rapamycin, promotes a diverse array of anabolic processes and suppresses catabolic processes such as autophagy. The significantly less-well understood TORC2, which displays insensitivity to acute rapamycin, is thought to promote cell proliferation and cell survival. Today, rapamycin or its analogues (rapalogues) are FDA (Food and Drug Administration)-approved in clinical medicine as immunosuppressive agents to blunt organ transplant rejection, in cardiology to reduce restenosis following angioplasty, and in oncology to treat renal cell carcinoma, thus underscoring the

Abbreviations used: AGC, cAMP-dependent protein kinase/cGMP-dependent protein kinase/protein kinase C; AMPK, AMP-activated kinase; BAD, Bcl-2/Bcl-X_L-antagonist, causing cell death; CBP, cAMP-response-element-binding protein; CCTβ, chaperonin-containing TCP-1 (t-complex protein 1) β; CRB, CBP-binding protein; CREMτ, cAMP-response-element modulator τ; deptor, DEP domain-containing mTOR-interacting protein; dS6K, *Drosophila* S6 kinase; 4EBP, eukaryotic initiation factor 4E-binding protein; eEF, eukaryotic elongation factor; eEF2K, eEF2 kinase; eIF, eukaryotic initiation factor; ER, endoplasmic reticulum; ERK, extracellular-signal-regulated kinase; FDA, Food and Drug Administration; FKBP, FK506-binding protein; FMRP, fragile X mental retardation protein; FRB, FKBP12–rapamycin-binding; GβL, G-protein β-protein subunit-like; GAP, GTPase-activating protein; GSK3, glycogen synthase kinase 3; HIF, hypoxia-inducible factor; HM, hydrophobic motif; IGF, insulin-like growth factor; IKK, inhibitor of nuclear factor-κB kinase; IRS, insulin receptor substrate; LTP, long-term potentiation; MAPK, mitogen-activated protein kinase; Mdm2, murine double minute 2; MEF, mouse embryonic fibroblast; MEK, MAPK/ERK kinase; mLST8, mammalian lethal with SEC13 protein; mSin1, mammalian stress-activated MAPK-interacting protein 1; mTOR, mammalian target of rapamycin; mTORC, mammalian TOR complex; NF-κB, nuclear factor-κB; NLS, nuclear localization sequence; PA, phosphatidic acid; PDCD4, programmed cell death 4; PDK, phosphoinositide-dependent kinase; PH, pleckstrin homology; PI3K, phosphoinositide 3-kinase; PIF, PDK-interacting fragment; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; PKG, cGMP-dependent protein kinase; PLD, phospholipase D; PP2A, protein phosphatase 2A; PRAS40, proline-rich Akt substrate of 40 kDa; PTEN, phosphatase and tensin homologue deleted on chromosome 10; PTM, post-translational modification; REDD1, regulated in development and DNA damage responses 1; raptor, regulatory associated protein of mTOR; rictor, rapamycin-insensitive companion of mTOR; RNAi, RNA interference; rpS6, ribosomal protein S6; RSK, ribosomal S6 kinase; S6K, S6 kinase; SGK, serum- and glucocorticoid-induced protein kinase; SKAR, S6K1 Aly/REF-like substrate; SREBP, sterol-regulatory-element-binding protein; TBK1, tumour necrosis factor-receptor-associated factor-associated NF-κB activator-binding kinase 1; TM, turn motif; TNF, tumour necrosis factor; TOP, terminal oligopyrimidine; TOR, target of rapamycin; TORC, TOR complex; TOS, TOR signalling; TSC/Tsc, tuberous sclerosis complex; ULK, unc-51-like kinase; YY1, Yin-Yang 1.

¹ These authors contributed equally to this review.

² To whom correspondence should be addressed (email dfingar@umich.edu).

important role of mTORC1 (mammalian TORC1) in physiology [4–7].

The ribosomal protein S6K (S6 kinase) and 4EBP [eIF4E (eukaryotic initiation factor 4E)-binding protein] represent the first TOR substrates identified in metazoans and remain the best characterized [8,9]. Since then, only a small set of additional *bona fide* TOR effectors have been identified. Today, we understand that S6K activation absolutely requires TORC1-mediated phosphorylation. S6K phosphorylates its own set of diverse targets, many of which promote protein production [10]. In a parallel pathway, TORC1-mediated phosphorylation of 4EBP1 initiates cap-dependent translation by eIF4E [10]. Thus TORC1 signals along parallel pathways to co-ordinately promote protein synthesis. rpS6 (ribosomal protein S6), a component of the 40S ribosome, represents the most extensively studied S6K substrate, although the biochemical consequence of rpS6 phosphorylation remains poorly understood [9,11].

In mammals, S6K represents a family composed of two distinct genes, S6K1 (*RPS6KB1*; also known as S6K α) and S6K2 (*RPS6KB2*; also known as S6K β) [12–18]. Mice singly null for S6K1 or S6K2 are born at normal Mendelian ratios, whereas mice null for both S6K1 and S6K2 display perinatal lethality [14,19]. Whole-body knockout of mTOR (mammalian TOR) in mice causes early embryonic lethality [e5.5 (embryonic day 5.5)] [20,21]. Taken together, these data reveal that non-S6K substrates mediate essential roles for mTORC1 during embryonic development, with S6Ks controlling physiological homeostasis post-development. Emerging evidence suggests that aberrant mTORC1–S6K1 signalling contributes to various pathological states, including diabetes, obesity, cancer, organ hypertrophy and aging-related pathology [2,22]. However, a mechanistic understanding of how S6K signalling contributes to many of these pathophysiological settings remains limited.

In the present review, we summarize the regulation and function of the TOR–S6K signalling axis in cellular and organismal physiology. Owing to limited research on S6K2, we will focus almost entirely on S6K1, although we will discuss S6K2 when appropriate. We will describe the complex biochemical mechanisms that govern the activation state of S6K1 within cells and describe how S6K1 integrates within cellular TOR signalling networks. We will review our understanding of the function of the TORC1–S6K1 axis in cellular function as well as physiology. To open, we provide an historical timeline of events that united TOR and S6K1.

HISTORICAL PERSPECTIVE

TOR and S6K share an inextricable biochemical link, yet possess unique histories that merged upon the discovery of the drug rapamycin, a naturally produced macrolide antibiotic. Rapamycin was discovered nearly a half-century ago in soil samples containing the bacterium *Streptomyces hygroscopicus* found on Easter Island, a South Pacific Polynesian island owned today by Chile and known as Rapa Nui to the native population [23]. This island, famous for its mysterious giant stone statues called ‘Moai’ that dot the coastline, was inhabited by an ancient civilization that precipitously failed prior to the arrival of the first Europeans, possibly due to mismanagement of vital natural resources within a fragile island ecosystem (i.e. deforestation) [24]. The first studies on rapamycin revealed the compound to possess anti-fungal activity due to G₁-phase arrest [6,25]. During the research of the efficacy of treating fungal infections with rapamycin, the compound was found to potently suppress the immune response in rats [26]. Discovery of the immunosuppressive properties of

rapamycin was pivotal both in its development as a clinical therapeutic, but also for basic biomedical research aimed at understanding mitogen-driven cellular growth and proliferation.

In mammals, rapamycin blocks the G₁- to S-phase transition in T-lymphocytes and thus inhibits T-cell proliferation by inhibiting signalling via interleukin-2 and its receptor [25]. As rapamycin generally reduces the proliferation of other cell types, to various degrees, rapalogues continue to be tested as anti-cancer chemotherapy drugs [6,7]. To identify genetic components that control rapamycin-induced toxicity in yeast, an elegant genetic screen was performed in 1991 in *Saccharomyces cerevisiae* [27]. Mutations in three genes, *Fpr1* [an orthologue of FKBP12 (FK506-binding protein 12)], *Tor1* and *Tor2*, conferred rapamycin resistance. Today, we understand that rapamycin bound to FKBP12 binds the TOR FRB (FKBP12–rapamycin-binding) domain, a short sequence lying immediately upstream of the C-terminal kinase domain (see Figure 1A). Thus rapamycin functions as an allosteric inhibitor rather than as an ATP-competitive catalytic inhibitor [6]. Soon thereafter in 1994–1995, several groups identified a mammalian counterpart to budding yeast Tor1/2 by immuno-affinity purification of FKBP12–rapamycin-interacting proteins, known today as mTOR (mammalian or mechanistic target of rapamycin) [1]. In an interesting evolutionary twist, higher eukaryotes (i.e. worms, flies and mammals) possess only one TOR gene, whereas the budding yeast *S. cerevisiae* and the fission yeast *Saccharomyces pombe* possess two Tor genes (*Tor1* and *Tor2*).

Although we know today that TOR, as part of TORC1, phosphorylates and activates the S6Ks in a manner potently sensitive to rapamycin, S6K1 was identified independently of either rapamycin or TOR. In the 1970s, it was discovered that diverse growth factors and mitogens promote phosphorylation of 40S rpS6, a component of the small ribosomal subunit, sparking intensive research efforts aimed at understanding this phenomenon. The 90 kDa RSK (ribosomal S6K) represents the first identified rpS6 kinase [28], now known to represent a family of three genes, RSK1–RSK3 [29]. The second rpS6 kinase, identified shortly thereafter, was the 70 kDa RSK (now called p70-S6K1) [12,13]. Thus two distinct but related kinases, both members of the AGC [PKA (cAMP-dependent protein kinase)/PKG (cGMP-dependent protein kinase)/PKC (protein kinase C)] kinase family, were found to phosphorylate rpS6 *in vitro* and, unfortunately, both were given similar names due to similar substrate preference, engendering significant confusion in the literature over the years. It is important to note that, although S6K1 was believed for many years to represent the physiological kinase for rpS6 in intact cells, persistent phosphorylation of rpS6 upon genetic knockout of S6K1 and S6K2 in mice ultimately revealed that RSK also represents a *bona fide* rpS6 kinase [19].

Since rapamycin was known to inhibit proliferation, the drug became an interesting candidate probe for the rpS6 pathway. Indeed, in 1992 rapamycin was found to potently inhibit mitogen-induced activation of S6K1 and the phosphorylation of rpS6 [30–32]. The rapamycin–FKBP12 complex, however, did not appear to directly interact with S6K1. Thus how rapamycin controlled S6K1 activity remained unclear. In 1995, rapamycin was found to ablate phosphorylation of S6K1 on Thr³⁸⁹ [33]. Consistent with a link between rapamycin and protein synthesis, in 1996 rapamycin was found to inhibit the phosphorylation of 4EBP1, an event that suppresses cap-dependent translation initiated by eIF4E [34]. A direct connection between S6K and mTOR was not demonstrated until 1997–1998 when mTOR was shown to directly phosphorylate S6K1 (Thr³⁸⁹) and 4EBP1 (Thr³⁷/Thr⁴⁶) by *in vitro* kinase assay and other *in vivo* approaches [35,36]. In 1999, mTOR-mediated phosphorylation of S6K1 (Thr³⁸⁹) *in vitro* was




Figure 1 Domain structures of S6K and mTOR

(A) mTOR domain structure and phosphorylation sites: mTOR contains a tandem series of HEAT (huntingtin, elongation factor 3, the PR65/A subunit of protein phosphatase 2A and TOR) repeats thought to mediate protein–protein interactions. Evolutionarily conserved FAT [FRAP (FKBP–rapamycin-associated protein)/ATM (ataxia telangiectasia mutated)/TRRAP (transformation/transcription domain-associated protein)] and FATC (FATC-terminal) domains flank the kinase domain. The rapamycin (Rapa)–FKBP12 complex binds the FRB domain. Upon activation, mTOR autophosphorylates on Ser²⁴⁸¹. Upon activation by mTORC1, S6K1 phosphorylates mTOR Ser²⁴⁴⁸ via a feedback loop. mTOR Ser¹²⁶¹, Ser²¹⁵⁹ and Thr²¹⁶⁴ phosphorylation promotes mTORC1 signalling. (B) S6K isoforms, domain structure and phosphorylation sites: S6K1 isoforms include p70-, p85- and p31-S6K1; alternative start site usage lengthens the p85- and p31-S6K1 N-termini by 23 amino acids (note that p31-S6K1 lacks most of the kinase domain). S6K2 isoforms include p54- and p56-S6K2; alternative start site usage lengthens the p56-S6K2 N-terminus by 13 amino acids. NLSs lie within the N-terminal extensions of p85-S6K1 and p56-S6K2, whereas S6K2 additionally contains an NLS within the C-terminus as well as a proline-rich domain (Pro). S6Ks contain an acidic N-terminal domain (NTD), kinase domain (KD), linker region and acidic C-terminal domain (CTD). The N-terminal domain contains the TOS motif, whereas the CTD contains the autoinhibitory pseudosubstrate domain and RSPRR motif. mTORC1 phosphorylates the HM site (Thr³⁸⁹) in the linker region and PDK1 phosphorylates the T-loop site (Thr²²⁹) within the kinase domain. Other regulatory phosphorylation (P) sites, including the TM site (Ser³⁷¹), are shown.

found to increase S6K1 activity towards rpS6 [37]. Throughout the 1990s, several other phosphorylation sites on S6K1 were identified that contributed to S6K1 regulation (described in more detail below). Thus S6K1 regulation occurs via complex multi-site phosphorylation. In 1998, it was shown that full activation of S6K1 requires not only phosphorylation of Thr³⁸⁹ by mTOR, but also phosphorylation of Thr²²⁹ by PDK1 (phosphoinositide-dependent kinase 1) [38,39]. The discovery of distinct TOR-containing complexes in 2002 in *S. cerevisiae* and mammals, a rapamycin-sensitive raptor (regulatory associated protein of mTOR)-containing TORC (TORC1) and a rapamycin-insensitive rictor (rapamycin-insensitive companion of mTOR)-containing TORC (TORC2), marked the next major turning point in the field [40–42].

S6K DOMAIN STRUCTURE AND CELLULAR REGULATION

S6K1 and S6K2 belong to the AGC kinase family, named for its three founding members PKA, PKG and PKC [43,44]. Although S6K1 was cloned in 1990 [12,13], S6K2 was not cloned until almost a decade later [14–18]. AGC kinases share several structural features that confer similar modes of

regulation. Their kinase domains exhibit a bilobal fold structure in which a small N-terminal lobe and a larger C-terminal lobe co-ordinate ATP binding [43,44]. At the beginning of the C-lobe lies an activation segment or loop (commonly known as the T-loop), phosphorylation of which effects conformational changes important for phosphoryl transfer. PDK1 represents the T-loop kinase for many AGC kinases, including S6K, RSK and Akt [also known as PKB (protein kinase B)]. Substrates engage a groove located near the T-loop. Two other important phosphorylation sites, the TM (turn motif) (so-named due to its location at the cusp of a structural turn in the PKA tail) and HM (hydrophobic motif) sequentially follow the kinase domain. The phosphorylated HM site engages a hydrophobic pocket within the N-lobe. The phosphorylated TM site stabilizes phospho-HM binding to the N-lobe hydrophobic pocket. Together, these three critical phosphorylation events stabilize a catalytically competent conformation [43,44].

S6K domain structure

The *S6K1* and *S6K2* genes each encode two protein isoforms generated by alternate ATG start site utilization [45]. S6K1 and

S6K2 share 84% identity within their kinase domains, with less homology in their N- and C-terminal regions (43% and 59% identity respectively) [15]. The more extensively studied 70 kDa S6K1 isoform (also known as S6K α 2) contains 502 amino acids, whereas the larger 85 kDa isoform (also known as S6K α 1) contains an additional 23 N-terminal amino acids (Figure 1B). Although p70-S6K1 predominantly localizes to the cytosol, the presence of an NLS (nuclear localization sequence) within the N-terminal extension of p85-S6K1 suggests that this isoform shuttles to the nucleus, although this notion has little experimental support. The 54 kDa S6K2 isoform (p54-S6K2; also known as S6K β 2) contains 482 amino acids, whereas the larger 56 kDa isoform (also known as S6K β 1) contains an additional 13 N-terminal amino acids (Figure 1B). Although the larger isoforms of S6K1 and S6K2 each contain an NLS in their N-terminal extensions, S6K2 uniquely contains an NLS in the C-terminus, suggesting that both S6K2 isoforms shuttle to the nucleus. A smaller splice variant of S6K1 has been reported, p31-S6K1, that is required for cellular transformation induced by the splicing factor SF2/ASF (splicing factor 2/alternative splicing factor) [46]. This 31 kDa isoform lacks most of the kinase domain, however, suggesting a function independent of kinase activity. Lastly, evidence exists for a 60 kDa splice isoform of S6K1, particularly in breast cancer cell lines [47].

The S6K1 and S6K2 proteins can be subdivided into several important regulatory domains (see Figure 1B): an acidic N-terminus that contains the TOS (TOR signalling) motif; the kinase domain that contains the T-loop; a linker region that contains the TM and HM sites; and a basic C-terminus containing an autoinhibitory pseudosubstrate domain. This C-terminal domain is unique to S6Ks among other AGC family members and experiences phosphorylation on multiple sites. In S6K2, a proline-rich region follows the pseudosubstrate domain, which may facilitate interaction with SH3 (Src homology 3)- and/or WW-domain-containing proteins. Co-ordination between these modular domains via hierarchical multi-site phosphorylation underlies the regulation of S6Ks.

S6K regulation by complex multi-site phosphorylation

Diverse growth factors and mitogens [i.e. serum, insulin/IGF (insulin-like growth factor), epidermal growth factor and PKC-promoting phorbol esters] activate the S6Ks [8,9]. The insulin/IGF pathway, the best-studied activator of S6Ks, signals via PI3K (phosphoinositide 3-kinase)/Akt to activate mTORC1 and thus the S6Ks [1,2]. In a PI3K-independent manner, the Ras/MAPK (mitogen-activated protein kinase) pathway also activates mTORC1. Both pathways, however, co-operate with other inputs to maximally activate the S6Ks. For example, downstream of PI3K, the Rho family G-proteins Cdc42 and Rac and the atypical PKC isoforms PKC ζ and PKC λ contribute to S6K1 activation [48,49]. In response to serum or insulin, S6K1 undergoes phosphorylation on at least eight well-mapped sites [8]. S6K1 activity absolutely requires phosphorylation on three critical sites: the T-loop site on the activation loop (Thr²²⁹ in p70-S6K1; Thr²⁵² in p85-S6K1), the TM site in the linker domain (Ser³⁷¹ in p70-S6K1; Thr³⁹⁴ in p85-S6K1), and the HM site, also in the linker domain (Thr³⁸⁹ in p70-S6K1; Thr⁴¹² in p85-S6K1), as mutagenic alanine residue substitutions at each of these sites abolishes S6K1 activity [50,51]. Owing to the essential nature of Thr³⁸⁹ phosphorylation, the mTORC1 inhibitor rapamycin potently blocks S6K1 activation by all known agonists [30–32], which correlates with dephosphorylation of the HM site, T-loop site and Ser⁴⁰⁴ in the linker region [33,52].

Over the past 20 years, a progressive series of S6K1 structure–function studies have elucidated the molecular steps that govern S6K1 activation by mitogens, revealing roles for complex interactions between specific domains and phosphorylation sites. This research has led to models for stepwise activation of S6K1 via complex multi-site phosphorylation [38,50,53–55]. In these models, S6K1 phosphorylation on multiple C-terminal sites represents an early event that facilitates mTORC1-mediated phosphorylation of the HM site (Thr³⁸⁹) in the linker domain and PDK1-mediated phosphorylation of the T-loop site (Thr²²⁹) on the activation loop. Owing to the strong positive co-operativity between the HM and T-loop sites, it has been difficult to determine unequivocally the temporal order of Thr³⁸⁹ and Thr²²⁹ phosphorylation events relative to each other. The current data support two models for activation of S6K via ordered phosphorylation, a conventional widely accepted model (Model 1; Figure 2A), and an alternate model (Model 2; Figure 2B). The temporal occurrence of TM site phosphorylation remains poorly understood, primarily because this phosphorylation event has received relatively scant attention by researchers. A recent study, however, suggests that TM site phosphorylation on Ser³⁷¹ by a constitutive kinase represents one of the first known phosphorylation events, one that may occur co-translationally [55] in a manner similar to the phosphorylation of the Akt TM site Thr⁴⁵⁰ [56]. Below, we first review the data that led to models for the activation of S6K1 by complex multi-site phosphorylation; secondly, we present two models for the temporal ordering of these phosphorylation events.


C-terminal phosphorylation

An early step in S6K1 activation in response to growth factors and mitogens involves priming phosphorylation on four proline-directed sites that lie in the C-terminal autoinhibitory pseudosubstrate domain (Ser⁴¹¹, Ser⁴¹⁸, Ser⁴²¹ and Ser⁴²⁴), which bears significant homology to the phosphorylated region of rpS6 [53,54]. It was first proposed in the early 1990s that, in the inactive state, the basic C-terminal pseudosubstrate domain interacts with the acidic N-terminus, which occludes the kinase domain and results in an inactive conformation (see Figure 2) [12,57]. Mitogen-induced C-terminal phosphorylation relieves this inhibition by releasing pseudosubstrate domain binding, thus inducing a conformational change that enables access to the HM and T-loop sites [12,57]. Although phosphorylation of these four C-terminal sites contributes to S6K1 activation, it is not critical. Mutation of these four sites to alanine residues, or deletion of 101 amino acids from the C-terminus (Δ CT), modestly reduces S6K1 activation, whereas substitution with phospho-mimetic residues (D3E) modestly increases basal activity in some reports [52,58,59]. Although the proline-directed mitogen-regulated MAPKs phosphorylate these C-terminal sites *in vitro* [53], the physiological kinases for these sites in intact cells remain unclear.

HM site phosphorylation by mTORC1

In 1998–1999, mTORC1 was shown to directly phosphorylate S6K1 on the HM site Thr³⁸⁹ to promote S6K1 activity (see Figure 2) [36,37]. Mutation of Thr³⁸⁹ to alanine (T389A) abolishes S6K1 activity, whereas substitution of an acidic glutamate residue for Thr³⁸⁹ (T389E) to mimic phosphorylation augments basal S6K1 activity in the absence of mitogens, thus rendering S6K1 partially constitutively active [50,59,60]. In 1995–1996, it was found that deletion of 30 amino acids from the N-terminus of p70-S6K1 (Δ NT) abolishes the serum-stimulated activation of S6K1 and the phosphorylation of the rapamycin-sensitive

A. Model 1: Conventional



B. Model 2: Alternate




Figure 2 Stepwise activation of S6K1 via multi-site phosphorylation

(A) Model 1: conventional model. The interaction of the C- and N-terminal domains results in autoinhibition of S6K1. Step 1: mitogens promote C-terminal domain (C) phosphorylation on multiple sites to induce a more relaxed conformation. Step 2: the release of the autoinhibitory C-terminal domain (CTD) enables mTORC1 access to the HM and thus phosphorylation of Thr³⁸⁹. Step 3: the release of the autoinhibitory CTD and phosphorylation on Thr³⁸⁹ enables PDK1-mediated phosphorylation of the T-loop on Thr²²⁹, resulting in full activation of S6K1. Phospho-Thr³⁸⁹ serves as docking site for PDK1. Owing to insufficient data, the temporal order of TM site phosphorylation (Ser³⁷¹) is not depicted. (B) Model 2: alternative model. Step 1: an unknown kinase phosphorylates the inactive form of S6K on the TM site Ser³⁷¹. Step 2: mitogens promote C-terminal domain (C) phosphorylation on multiple sites to induce a more relaxed conformation. Step 3: the release of the autoinhibitory C-terminal domain enables PDK1 access to the T-loop. Step 4: PDK1-mediated phosphorylation of Thr²²⁹ promotes mTORC1-mediated phosphorylation on the HM site, Thr³⁸⁹. KD, kinase domain; N, N-terminal domain. An animation of this Figure is available at <http://www.BiochemJ.org/bj/441/0001/bj4410001add.html>.

sites Thr³⁸⁹, Thr²²⁹ and Ser⁴⁰⁴ [61–63]. Strikingly, additional deletion of the C-terminus (Δ NT/ Δ CT) restores kinase activity (although to levels significantly less than maximal, 5–15 %) and restores phosphorylation of the rapamycin-sensitive sites. These results indicated that the N-terminus of S6K1 serves two critical functions: first, it functions in the reception of an activating input critical for Thr³⁸⁹ and Thr²²⁹ phosphorylation; and, secondly, it suppresses an inhibitory function mediated by the C-terminus. In 2002, a short sequence at the extreme N-terminus of p70-S6K1 (FDIDL; amino acids 5–9) was identified to be critical for mitogen-stimulated S6K1 activation and phosphorylation of rapamycin-sensitive sites, and was named the TOS motif [59]. Deletion of the TOS motif or mutagenic inactivation of the motif (F5A mutation within the FDIDL sequence) abolishes S6K1 kinase activity as well as Thr³⁸⁹ and Thr²²⁹ phosphorylation, thus mapping the critical regulatory function of the N-terminus to a specific motif. As in Δ NT/ Δ CT, deletion of the C-terminus from the F5A mutant (F5A- Δ CT) partially restored kinase activity and Thr³⁸⁹ phosphorylation. 4EBP1, the other well-characterized mTOR-regulated target, was also found to contain a TOS motif (FEMDI; amino acids 114–118 at the extreme C-terminus) [59]. In 2003, several groups demonstrated that the S6K1 and 4EBP1 TOS motifs directly bind raptor, a critical mTOR-interacting scaffold protein, thus enabling mTORC1 to engage substrates and to mediate phosphorylation of rapamycin-sensitive sites [64,65].

The discovery that the S6K1 N-terminus also functions to suppress an inhibitory C-terminal function was not elucidated further until 2005, when a motif (RSPRR) was identified in the C-terminus of p70-S6K1 (amino acids 410–414), shortly after the linker region (see Figure 2) [66]. Mutation of the RSPRR motif within the dead Δ NT or TOS motif-mutant (F5A) backbone (Δ NT-R3A or F5A-R3A) rescued insulin-stimulated Thr³⁸⁹

phosphorylation and S6K1 activation. Thus, in a mutant lacking an intact TOS motif (i.e. Δ NT or F5A), an intact RSPRR motif suppresses mTOR-mediated Thr³⁸⁹ phosphorylation, and thus inactivation of the RSPRR motif rescues activity. The mechanism by which the S6K1 TOS motif suppresses the inhibitory RSPRR motif remains a mystery, although one hypothesis posits that the RSPRR motif functions as a docking site for a negative regulator, such as a phosphatase, that is suppressed by mTORC1 [66]. Indeed, weak evidence suggests the involvement of a phosphatase in the regulation of mTORC1 substrates (described in more detail below).

T-loop site phosphorylation by PDK1

Maximal S6K1 activation in response to growth factors requires the co-ordinate phosphorylation of both Thr²²⁹ and Thr³⁸⁹ [38,39,50]. Using *in vitro* and *in vivo* approaches, in 1998 the constitutive kinase PDK1 was shown to directly phosphorylate S6K1 on the T-loop site Thr²²⁹ to promote S6K1 activity [38,39], similar to the earlier identified role of PDK1 in phosphorylation of the Akt T-loop site Thr³⁰⁸ [67]. As S6K1 is enzymatically dead in *PDK1*^{-/-} embryonic stem cells or when mutated to T229A, S6K1 activation absolutely requires T-loop phosphorylation [50,68]. *In vitro* phosphorylation of S6K1 by PDK1 was found to activate S6K1- Δ CT significantly better than full-length S6K1, but to poorly activate an S6K1 mutant bearing alanine residue substitutions at C-terminal phosphorylation sites [38]. These results suggested that an intact unphosphorylated C-terminus blocks access of PDK1 to the activation loop. Moreover, PDK1 poorly activated S6K1 T389A- Δ CT or T371A- Δ CT *in vitro*, revealing required roles for the HM and TM sites in PDK1-mediated S6K1 activation [38].

S6K1 T-loop phosphorylation (Thr²²⁹) relies upon the PIF (PDK-interacting fragment)-binding pocket found within the PDK1 kinase domain, but does not depend on the PDK1 PH (pleckstrin homology) domain [69]. Conversely, Akt T-loop phosphorylation (Thr³⁰⁸) does not require the PIF-binding pocket of PDK1, yet is highly dependent on the PDK1 PH domain [70]. Clearly, a distinction exists among PDK1 substrates in that PtdIns(3,4,5)P₃-dependent activation at the membrane (e.g. Akt) relies upon PH domain function, whereas PtdIns(3,4,5)P₃-independent activation in the cytosol (e.g. S6K1) relies upon the PIF-binding pocket for PDK1 interaction. The observation that Thr²²⁹ phosphorylation on S6K1 occurs in a PI3K-dependent manner (sensitive to wortmannin) in response to insulin [71] probably reflects co-operativity between Thr²²⁹ phosphorylation and Thr³⁸⁹ phosphorylation, as Thr³⁸⁹ phosphorylation occurs in a PtdIns(3,4,5)P₃-dependent manner via Akt/mTORC1. A recent crystal structure has confirmed that S6K1 bearing a PDK1-phosphorylated T-loop relative to an unphosphorylated T-loop induces local ordering of this normally disordered segment [72].

TM site phosphorylation

Although S6K1 activation absolutely requires TM site phosphorylation on Ser³⁷¹ (S6K1-S371A is enzymatically dead), the regulation and function of this phosphorylation event, as well as the identity of the Ser³⁷¹ kinase, remains unclear [51]. In some reports, serum or insulin stimulation modestly increases Ser³⁷¹ phosphorylation (~2-fold) in a rapamycin- and wortmannin-sensitive manner [59,71]. S6K1 in growth-factor-deprived cells, however, bears significant Ser³⁷¹ phosphorylation that is rapamycin-resistant. As kinase-dead S6K1 displays normal Ser³⁷¹ phosphorylation, this site does not represent a site of autophosphorylation [51]. As addition of a T389E substitution fails to restore any kinase activity to the dead S371A mutant, these data suggest that Ser³⁷¹ phosphorylation plays an important yet independent role in regulating the intrinsic catalytic activity of S6K1 [51]. Lastly, mTOR reportedly phosphorylates Ser³⁷¹ *in vitro*, and overexpression of TOR in intact cells modestly increases Ser³⁷¹ phosphorylation, whereas overexpression of a kinase-dead mTOR allele modestly reduces Ser³⁷¹ phosphorylation [71]. These results suggest that mTOR contributes to the regulation of S6K1 Ser³⁷¹ phosphorylation. As phospho-Ser³⁷¹ does not correlate well with mTORC1 activity, another kinase may co-operate with mTOR to regulate Ser³⁷¹ phosphorylation. By analogy to Akt in which TM site phosphorylation (Thr⁴⁵⁰) occurs co-translationally and thus represents an early phosphorylation event [56], it is tempting to speculate that S6K1 TM site phosphorylation also represents an early event that occurs co-translationally prior to T-loop and HM site phosphorylation. Indeed, a recent report supports such an idea, as Ser³⁷¹ phosphorylation occurs simultaneously with the production of S6K1 protein from a transfected plasmid [55].

Models: stepwise activation of S6K1 via ordered multi-site phosphorylation

Investigation of Thr²²⁹ and Thr³⁸⁹ phosphorylation not only revealed strong positive co-operativity between these sites for S6K1 activation, but also addressed their temporal relationship to each other. The results support two models for the stepwise activation of S6K1 via ordered multi-site phosphorylation (Figure 2). The conventional Model 1 suggests that mTORC1-mediated phosphorylation of Thr³⁸⁹ occurs prior to PDK1-mediated phosphorylation of Thr²²⁹ (Figure 2A) [38,39,60]. In this model, based largely on analogy to PDK1-mediated activation of RSK2, phospho-Thr³⁸⁹ becomes a docking site for

PDK1, which then phosphorylates Thr²²⁹ on the activation loop [73]. The alternative Model 2 suggests that PDK1-mediated phosphorylation of Thr²²⁹ occurs prior to mTORC1-mediated phosphorylation of Thr³⁸⁹ (Figure 2B) [50,55].

In support of Model 1, an S6K1-T389A mutant exhibits reduced growth-factor-stimulated Thr²²⁹ phosphorylation in intact cells [50]. *In vitro*, PDK1 phosphorylates S6K1-T389E-D3E significantly better than wild-type, T389E or D3E, revealing important roles for the HM site and C-terminal phosphorylation in PDK1-mediated S6K1 phosphorylation [39,60]. In support of Model 2, an S6K1-T229A mutant exhibits reduced growth-factor-stimulated Thr³⁸⁹ phosphorylation in intact cells; S6K1 bears substantial Thr²²⁹ but not Thr³⁸⁹ phosphorylation in serum-deprived cells, and *PDK1*^{-/-} embryonic stem cells lack Thr³⁸⁹ phosphorylation [50,68,74]. A recent study demonstrates that mTOR-mediated phosphorylation of S6K1 on Thr³⁸⁹ *in vitro* (using a C-terminally truncated S6K1 allele) requires prior *in vitro* phosphorylation by PDK1 on Thr²²⁹ [55]. Owing to insufficient data, the widely accepted Model 1 does not order TM site phosphorylation on Ser³⁷¹ relative to HM and T-loop site phosphorylation. Recent data supporting alternate Model 2, however, suggest that TM site phosphorylation represents an early event that occurs prior to HM and T-loop site phosphorylation [55].

Generation of rapamycin-resistant S6K1 mutants

S6K1 structure–function analysis has generated various rapamycin-resistant mutants, which have proven useful as tools to identify mTORC1-regulated cellular processes mediated by S6K1 [75–77]. ΔNT/ΔCT represents the first rapamycin-resistant mutant [61]. Although possessing low intrinsic catalytic activity, this mutant bears complete rapamycin resistance. Addition of phospho-mimetic T389E to ΔNT/ΔCT (ΔNT-T389E-ΔCT) creates a constitutive kinase with full activity and complete rapamycin resistance [59]. Similarly, targeted inactivation of the C-terminal RSPRR-motif within the F5A-T389E backbone (F5A-T389E-R3A) recapitulates the behaviour of the F5A-T389E-ΔCT mutant [66]. This F5A-T389E-R3A mutant thus represents an improved rapamycin-resistant S6K1 allele due to its full-length nature.

The presence of Thr³⁸⁹ phosphorylation on S6K1-ΔNT/ΔCT isolated from rapamycin-treated cells questioned the idea that mTORC1 represents the sole S6K1 Thr³⁸⁹ kinase. In ΔNT/ΔCT, serum and insulin promote Thr³⁸⁹ phosphorylation and kinase activation in a completely rapamycin-resistant manner, suggesting that a rapamycin-insensitive kinase mediates Thr³⁸⁹ phosphorylation [61,63]. This conundrum was resolved in 2005 with the discovery that rapamycin-insensitive mTORC2 mediates non-physiological S6K1 Thr³⁸⁹ phosphorylation in S6K1 mutants lacking a C-terminus [78]. A notable feature of S6Ks is their rather atypical C-terminal extension not found in other AGC kinase family members. The absence of this C-terminal extension in Akt may explain why mTORC2 mediates phosphorylation of the Akt HM site Ser⁴⁷³. This knowledge explains the range of sensitivities to rapamycin displayed by various S6K1 mutants. In the dead ΔNT allele, mTORC1 (mTOR/raptor) cannot dock to S6K1 and phosphorylate Thr³⁸⁹, and mTORC2 (mTOR/rictor) cannot phosphorylate Thr³⁸⁹ due to steric hindrance imposed by the extended C-terminus [78]. In the partially rapamycin-resistant ΔCT mutant, both rapamycin-sensitive mTORC1 and rapamycin-insensitive mTORC2 co-operatively mediate Thr³⁸⁹ phosphorylation. In ΔNT/ΔCT (and F5A-ΔCT), only rapamycin-insensitive mTORC2 mediates Thr³⁸⁹ phosphorylation.

S6K1 regulation by other less well-defined modes

Although phosphorylation represents the best understood mechanism underlying S6K1 regulation, roles for other PTMs (post-translational modifications) have been proposed, including phosphatase-mediated dephosphorylation, acetylation, ubiquitination and regulated subcellular localization.

Dephosphorylation

Addition of rapamycin to cycling cells in culture results in rapid dephosphorylation of S6K1 (Thr³⁸⁹), suggesting action by a regulated phosphatase. Indeed, S6Ks have been suspected to represent targets of PP2A (protein phosphatase 2A)-like phosphatases. In *S. cerevisiae*, TOR regulation of several substrates occurs via suppression of PP2A-like phosphatases [79]. In mammals, PP2A reportedly co-immunoprecipitates with S6K1 [80]; moreover, an independent study showed that PP2A binds wild-type but not Δ NT/ Δ CT S6K1 [81]. It is important to note, however, that since the late 1990s there has been little follow-up regarding the role of PP2A-like phosphatases in S6K1 regulation. Recent work in *Drosophila melanogaster* demonstrates that genetic ablation of the PP2A regulatory subunit B' (PP2A-B') leads to dS6K (*Drosophila* S6K) deregulation and a variety of metabolic defects [82]. High levels of phosphorylated S6K (on Thr³⁸⁹) were also detected in human cells upon knockdown of PPP2R5C, the human PP2A-B' orthologue [82]. Whether mTOR suppresses a PP2A-like phosphatase to modulate S6K1 Thr³⁸⁹ phosphorylation in mammals as in yeast remains unclear at this time.

Acetylation and ubiquitination

Although significantly less well understood relative to protein phosphorylation, acetylation and ubiquitination represent additional PTMs that modify protein function. Two acetyltransferase enzymes, p300/CBP (cAMP-response-element-binding protein-binding protein) and PCAF (p300/CBP-associated factor), reportedly interact with and acetylate S6K1 and S6K2 both *in vitro* and *in vivo* [83]. Acetylation of S6K1 occurs at the extreme C-terminus (Lys⁵¹⁶) in response to mitogens, and acetylation and phosphorylation events appear to occur independently of one another [84]. Although the function of acetylation remains unclear, this PTM may serve to stabilize S6Ks, as treatment of cells with the HDAC (histone deacetylase) inhibitor trichostatin A increases S6K2 acetylation and protein abundance [83]. Polyubiquitination of proteins induces their degradation by the 26S proteasome. Both S6K1 and S6K2 appear to experience this PTM in response to mitogen stimulation [85,86]. Identified in a yeast two-hybrid screen as an S6K1-interacting protein, the ubiquitin ligase ROC1 was shown to interact with and ubiquitinate S6K1 [87]. As RNAi (RNA interference) against ROC1 increases steady-state levels of S6K1, these results suggest that polyubiquitination may destabilize S6K proteins and thus may function as a mechanism for signal attenuation. Indeed, it was reported recently that Akt phosphorylation on its HM site (Ser⁴⁷³) induces Akt polyubiquitination and subsequent degradation as a means to attenuate Akt signalling [88]. Future work will be required to define the roles of acetylation and polyubiquitination in S6K regulation and function.

Subcellular localization

Whether subcellular localization of S6K1 and S6K2 contributes to their regulation and/or function remains an important unresolved question. The lack of antibodies that specifically detect

endogenous S6K1 and S6K2 isoforms by immunofluorescence of fixed cells has precluded such a traditional approach. Thus the limited analysis performed so far has relied on either immunofluorescence of tagged exogenously-expressed kinases or cellular fractionation, a challenging biochemical technique. Treatment of cells with the nuclear export inhibitor leptomycin B causes p70-S6K1, p54-S6K2 and mTOR to accumulate in the nucleus (even though p70-S6K1 does not possess an obvious NLS), indicating that these isoforms shuttle between the cytosol and nucleus [89,90]. p54-S6K2 was found to localize predominantly to the nucleus (probably due to the presence of both N- and C-terminal NLS motifs), and thus leptomycin B had little effect [17,90]. Activation of PKCs via the phorbol ester PMA induced the phosphorylation of both S6K2 isoforms within their C-terminal NLS motifs, which promoted the shuttling of p54- but not p56-S6K2 from the nucleus to the cytosol [90]. It was proposed that NLS phosphorylation blunted NLS function. These data support the idea that S6Ks may shuttle between different subcellular compartments. More research will be required, however, to understand whether S6K subcellular localization controls S6K regulation and/or cellular function.

S6K2 regulation

Although the majority of studies aimed at elucidating S6K regulation have focused on S6K1, more limited results suggest that S6K2 regulation occurs via similar, although probably non-identical, mechanisms [91–93]. Insulin, serum and phorbol esters activate S6K2, similar to S6K1, and seven of eight phosphorylation sites found in S6K1 are also conserved in S6K2 (Thr²²⁸, Ser³⁷⁰, Thr³⁸⁸, Ser⁴⁰³, Ser⁴¹⁰, Ser⁴¹⁷ and Ser⁴²³ on p54-S6K2) [15–17,93]. Insulin-stimulated activation of S6K2 requires C-terminal phosphorylation (on Ser⁴¹⁰, Ser⁴¹⁷ and Ser⁴²³), yet the C-terminus of S6K2 exerts a more potent inhibitory effect on kinase function than the C-terminus of S6K1 [91,92]. Wortmannin and rapamycin block insulin-stimulated activation of S6K2 [15–17,93], suggesting that mTORC1 phosphorylates the HM site (Thr³⁸⁸) and PDK1 phosphorylates the activation loop site (Thr²²⁸), similar to S6K1. Consistent with these data, phosphorylation of S6K2 on the PDK1 site (Thr²²⁸) and the mTORC1 site (Thr³⁸⁸) is required for kinase activity, as alanine residue substitution mutants at these sites render S6K2 enzymatically dead [93]. Unlike S6K1, phospho-mimetic substitution at Thr³⁸⁸ (T388E) renders S6K2 fully active, as well as wortmannin- and rapamycin-resistant [93]. Lastly, S6K2 localizes predominantly to the nucleus via a C-terminal NLS (KKSK⁴⁷⁴RGR), disruption of which results in cytosolic localization [17]. Mutation of K474M within the NLS had no effect on S6K2 kinase activity, however, indicating that S6K2 activation does not require its ability to localize to the nucleus [17].

mTOR SIGNALLING NETWORKS

The absolute requirement for mTOR in S6K activation renders understanding of mTOR regulation and mTORC network wiring essential if we hope to fully understand S6K regulation and function. TOR belongs to the PIKK (PI3K-related kinase) superfamily, yet acts as a serine/threonine protein kinase, not a lipid kinase [1,2]. TOR functions as an environmental sensor, as it responds to and integrates diverse cellular signals (e.g. growth factors and mitogens, nutrients, energy, stress) to modulate cell physiology in an appropriate manner. TOR forms the catalytic core of at least two known multi-subunit complexes, TORC1 and TORC2. These complexes contain shared as well as unique partners that confer differential sensitivity to rapamycin, regulation and substrate selectivity. Acute treatment of cells with




Figure 3 Regulation, substrates and functions of the mTORC1–S6K1 signalling network

S6K1 activation occurs via co-ordinated phosphorylation by mTORC1 and PDK1. Growth factors/mitogens, amino acids and energy activate, whereas cellular stresses such as hypoxia and depleted ATP levels suppress, the mTORC1–S6K1 axis. Through its identified substrates, and other unclear mechanisms, S6K1 promotes several broad cellular processes: protein production, cell growth/size, cell survival, gene transcription, adipocyte differentiation and synaptic plasticity. S6K1 regulates protein production in several ways: mRNA processing (via SKAR and CBP80), cap-dependent translation initiation (via PDCD4, eIF4B and co-ordination with 4EBP1) and translational elongation (via eEF2 kinase); additionally, S6K1 may regulate ribosome function (via rpS6; function unknown) and nascent protein folding (via CCT β). S6K1 participates in cell survival signalling (via BAD, Mdm2, GSK3, and possibly through rictor (mTORC2)), regulates two transcription factors [CREM τ and oestrogen receptor α (ER α)], modulates synaptic plasticity (via FMRP) and promotes negative feedback on PI3K signalling (via IRS1, thus suppressing insulin/IGF sensitivity, and rictor). Refer to the main text for more detail. Key: black arrows, activation; black blocks, inhibition; circled question mark, unclear function; grey broken arrow, activates through unknown effectors; yellow circled P, phosphorylates; orange ovals, S6K substrates; green arrows/text, positive mTORC1–S6K1 inputs; brown arrows/text, negative mTORC1–S6K1 inputs. IR, insulin receptor; IGF, insulin-like growth factor receptor.

rapamycin inhibits mTORC1 but not mTORC2 [6], although chronic rapamycin treatment inhibits mTORC2 by blocking complex assembly [94].

In mammals, both mTORC1 and mTORC2 contain mTOR, mLST8 (mammalian lethal with SEC13 protein)/G β L (G-protein β -protein subunit-like) and deaptor (DEP domain-containing mTOR-interacting protein) [3,95] (Figure 3). The presence of raptor and PRAS40 (proline-rich Akt substrate of 40 kDa) defines mTORC1, whereas the presence of rictor, mSin1 (mammalian stress-activated MAPK-interacting protein 1) and protor 1/2 (protein observed with rictor 1/2) defines mTORC2. Raptor and rictor serve as critical scaffolds that control complex assembly, regulation by cellular signals and substrate choice. Deaptor functions as a negative regulator of both complexes, whereas the function of mLST8/G β L remains unclear. Within mTORC1, PRAS40 suppresses mTORC1 signalling, either by functioning as a *bona fide* inhibitor or competitive substrate. It is important to note that the roles of the various mTOR-associated proteins

in mTORC1/2 function remain incompletely defined. Today, we understand the regulation of mTORC1 significantly better than mTORC2.

mTORC1 regulation

mTORC1 responds to a diverse array of upstream signals, including growth factors, mitogens, and cytokines, amino acids, energy and cell stress. Below, we review several of the best-understand pathways that control mTORC1 signalling, thus enabling mTORC1 to function as an environmental sensor (Figure 3).

Insulin/PI3K signalling

The insulin/PI3K pathway represents the best-characterized activator of mTORC1 [1,95]. Binding of insulin or IGF to its cognate cell-surface receptor leads to tyrosine phosphorylation

of IRS (insulin receptor substrate) proteins, followed by recruitment and activation of PI3K. Generation of $\text{PtdIns}(3,4,5)P_3$ on the plasma membrane by PI3K leads to PDK1-mediated phosphorylation of Akt on its T-loop site (Thr³⁰⁸) and mTORC2-mediated activation on its HM site (Ser⁴⁷³) [67,96]. Activated Akt then phosphorylates Tsc2 (tuberous sclerosis complex 2) on several sites (Ser⁹³⁹ and Thr¹⁴⁶²) to suppress the inhibitory effect of the Tsc1–Tsc2 complex on mTORC1, thus leading to increased mTORC1 signalling [97]. In addition to phosphorylating Tsc2, Akt phosphorylates PRAS40 (Ser²⁴⁶) to disrupt the inhibitory raptor–PRAS40 interaction, thus promoting mTORC1 signalling [98,99]. Tsc1 and Tsc2 function as tumour suppressors [100]. Loss of either causes the autosomal dominant TSC, a disease characterized by benign tumour formation in various organs, including the brain, kidneys and heart. Tsc2 (also called tuberlin) acts as a GAP (GTPase-activating protein) toward the Ras-like small GTP-binding protein Rheb, whereas Tsc1 (also called hamartin) functions to maintain the Tsc1–Tsc2 complex stability [101,102]. Rheb represents the most proximal positive regulator of mTORC1 known to date. Rheb reportedly binds weakly to the mTOR kinase domain to enhance substrate recruitment in a GTP-dependent manner [103,104]. Upon activation by insulin, mTOR within mTORC1 and mTORC2 autophosphorylates (Ser²⁴⁸¹); thus mTOR Ser²⁴⁸¹ autophosphorylation monitors intrinsic catalytic activity of mTOR complexes [105].

The current model posits that insulin/PI3K signalling leads to Akt-mediated inactivation of Tsc1/Tsc2 function, which in turn promotes Rheb-GTP-mediated activation of mTORC1. However, many details implicit to this model remain incomplete. For example, it remains unclear how Akt-mediated phosphorylation of Tsc2 suppresses Tsc1–Tsc2 function. Does Tsc2 phosphorylation inhibit Tsc2 GAP activity, dissociate Tsc2 from Tsc1, and/or induce Tsc2 degradation [100]? The mechanism by which Rheb promotes mTORC1 signalling also remains poorly understood, and the GEF (guanine-nucleotide-exchange factor) that loads Rheb with GTP remains unknown. Emerging data also indicate that phosphorylation of mTOR and its interacting partners (e.g. raptor, rictor, PRAS40 and deptor) contributes to mTORC1 and mTORC2 regulation. For example, phosphorylation of mTOR on several sites (Ser¹²⁶¹, Ser²¹⁵⁹ and Thr²¹⁶⁴) promotes mTORC1 signalling and cell growth [106,107]. In response to the appropriate signals, mTOR, RSK and ERK (extracellular-signal-regulated kinase) phosphorylate raptor, whereas Akt and mTOR phosphorylate PRAS40, events that promote mTORC1 signalling [98,99,108–113]. Additionally, growth factor and nutrient signals promote the phosphorylation and degradation of deptor by the ubiquitin–proteasome system, which results in increased mTORC1 and mTORC2 signalling [114].

Ras/MAPK signalling

Independent of the insulin/PI3K/Akt pathway, the mitogen-activated Ras/MEK (MAPK/ERK kinase)/MAPK signalling cascade activates mTORC1 by converging on Tsc1/Tsc2. Reminiscent of Akt phosphorylation, ERK and its substrate RSK phosphorylate Tsc2 (Ser⁵⁴⁰, Ser⁶⁴⁴ and Ser¹⁷⁹⁸ respectively), which inhibits Tsc1/Tsc2 and thus promotes Rheb-mediated mTORC1 activation [115,116]. The Ras/MAPK pathway also converges on raptor to promote mTORC1 function. Both ERK and RSK phosphorylate raptor (on Ser⁸/Ser⁶⁹⁶/Ser⁸⁶³ and Ser⁷¹⁹/Ser⁷²¹/Ser⁷²² respectively) [110,111]. Thus the PI3K/Akt and Ras/MAPK pathways signal in a parallel manner to regulate Tsc1/Tsc2 and raptor function, indicating a level of functional redundancy between these two mitogen-regulated signalling systems.

PLD (phospholipase D) signalling

PA (phosphatidic acid), a lipid second messenger produced by PLD-mediated hydrolysis of phosphatidylcholine, binds the mTOR FRB domain to promote mTORC1 signalling in a rapamycin-sensitive manner [117]. Growth factors and amino acids activate PLD, which appears to function downstream of Rheb-GTP [118]. More recently, it was reported that PA promotes assembly of both mTORC1 and mTORC2, which accordingly promotes signalling [119]. Interestingly, rapamycin competes for PA binding to mTOR, and much higher concentrations of rapamycin are required for PA–mTORC2 than PA–mTORC1 competition. These results provide an intriguing molecular model for the rapamycin insensitivity of mTORC2 relative to mTORC1.

Cytokine signalling

Downstream of TNF α (tumour necrosis factor α), activated IKK β [inhibitor of NF- κ B (nuclear factor- κ B) kinase- β] binds to and phosphorylates Tsc1 (Ser⁴⁸⁷ and Ser⁵¹¹), resulting in Tsc1–Tsc2 dissociation, mTORC1 activation and increased tumour angiogenesis and insulin resistance [120,121]. Additionally, insulin and TNF α promote mTORC1 signalling via a mechanism that involves direct interaction of IKK α with mTORC1 in an Akt-dependent manner [122,123], which promotes NF- κ B-dependent transcriptional activity [124]. Moreover, recent studies suggest that the IKK-related kinase TBK1 (TNF-receptor-associated factor-associated NF- κ B activator-binding kinase 1) phosphorylates Akt on both its T-loop and HM sites, Thr³⁰⁸ and Ser⁴⁷³ respectively [125–127]. Taken together, these results reveal novel links between innate immune signalling and mTOR that warrant further exploration.

Nutrient sensing

Sufficient levels of amino acids are absolutely required for mTORC1 function. Thus even in the presence of abundant growth factors, withdrawal of amino acids, particularly the branched-chain amino acids leucine and isoleucine, rapidly inhibits mTORC1 signalling. As amino acid withdrawal suppresses mTORC1 signalling in Tsc-deficient cells [128], amino acid sensing appears to converge on mTORC1 downstream of Tsc1/2. The bidirectional amino acid permease SLC7A5–SLC3A2 (where SLC, solute carrier family), which imports leucine across the plasma membrane into the cell while exporting glutamine out, is essential for mTORC1 activation [129]. Although the mechanism by which cells sense amino acid levels remains a mystery, several biochemical mediators that link amino acid sensing to mTORC1 have been reported, including hVPS34, a class III lipid kinase known to function in vacuolar sorting and autophagy in yeast, the MAP4K3 (MAPK kinase kinase 3), the RalA GTPase and the Rag GTPases [1,2,95].

The Rag family of GTPases represents the best-characterized link between amino acid sensing and mTORC1 [130,131]. Rags function as heterodimers in which RagA or RagB dimerizes with RagC or RagD, with each Rag class bearing opposing nucleotide-bound states. Upon amino acid stimulation, active Rag heterodimers (i.e. RagB^{GTP}–RagD^{GDP}) bind mTORC1 directly via raptor, which enables mTORC1 to localize to a Rab7-positive late endosomal/lysosomal membrane compartment that has been shown to also contain exogenously expressed Rheb [130]. Endogenous Rheb, however, has not been localized to this compartment. Such a model explains why growth-factor-induced mTORC1 activation absolutely requires amino acids: mTORC1 must reside in the correct subcellular compartment to undergo

activation by Rheb. In a follow-up study, a complex containing three proteins (MP1, p14 and p18) renamed 'Ragulator' was found to reside on lysosomal membranes and to bind to and recruit Rag heterodimers [132]. Thus, upon amino acid stimulation, active Rag heterodimers bound to the Ragulator complex recruit mTORC1 to lysosomes for activation in a Rheb-dependent manner. Interestingly, the MP1-p14-p18 complex was first identified as a scaffold for MEK that is critical for the endosomal localization and activation of a branch of the MAPK pathway [133]. Thus it appears as though the Ragulator complex regulates at least two signalling systems via endosomal-anchored spatial control. Indeed, forced localization of mTORC1 to the lysosomal surface eliminates the requirement of amino acids, Rag GTPases and the Ragulator for mTORC1 activation, but not the requirement for Rheb [132]. Recently, Rab family GTPases, which function in endocytic trafficking (e.g. Rab5 and Rab7), were found to modulate mTORC1 signalling [134]. Additionally, the Rho family GTPase Rac1 was recently reported to positively regulate mTORC1 (and mTORC2) by directly binding mTOR and controlling its localization to specific internal membranes [135]. These results lend support to the idea that subcellular trafficking of mTORC1 contributes to its regulation, with important roles for small G-proteins.

Energy and stress sensing

Diverse forms of cell stress down-regulate mTORC1 signalling, including glucose withdrawal, hypoxia, DNA damage and ER (endoplasmic reticulum) stress [95]. Energy stress induced by glucose withdrawal or by chemical inhibition of glycolysis or mitochondrial respiration leads to a rapid fall in cellular ATP levels. The resulting rise in the cellular AMP/ATP ratio activates AMPK (AMP-activated kinase), a trimeric complex composed of $\alpha/\beta/\gamma$ subunits [136]. Activated AMPK phosphorylates Tsc2 (Thr¹²²⁷ and Ser¹³⁴⁵) to augment Tsc1-Tsc2-mediated inhibition of mTORC1 [137]. In Tsc-deficient cells, however, energy stress still induces partial inhibition of mTORC1, suggesting a Tsc-independent mechanism for AMPK regulation of mTORC1. Indeed, AMPK phosphorylates raptor (Ser⁷⁹² and Ser⁷²²) to down-regulate mTORC1 in response to energy stress [138]. Independent of AMPK, energy stress inhibits mTORC1 by suppressing Rheb-GTP loading via a mechanism involving PRAK-mediated phosphorylation (Ser¹³⁰) and inhibition of Rheb in response to p38 β MAPK signalling [139]. Thus AMPK-dependent and -independent mechanisms co-operate to down-regulate mTORC1 in response to energy stress.

Hypoxia also reduces ATP levels, thus leading to AMPK-mediated down-regulation of mTORC1 by mechanisms described above. Via a mechanism independent of cellular ATP levels, hypoxia stabilizes the HIF1 (hypoxia-inducible factor 1) transcription factor, which induces expression of a number of survival genes, including REDD1 (regulated in development and DNA damage responses 1) [140,141]. Although the mechanism of action of REDD1 remains poorly understood, REDD1 appears to bind 14-3-3 proteins, inducing their dissociation from Tsc2 and leading to Tsc1-Tsc2 activation and thus mTORC1 inhibition [142]. In response to DNA damage, stabilization and activation of the p53 transcription factor and tumour suppressor leads to induction of sestrins 1 and 2, which bind to and activate AMPK via an unknown mechanism to down-regulate mTORC1 [143]. ER stress results from the accumulation of misfolded proteins, which activates a signal transduction cascade known as the unfolded protein response that slows global protein synthesis. Indeed, ER stress leads to transcriptional up-regulation of REDD1, resulting

in down-regulation of mTORC1 signalling [144]. Clearly, diverse signals of cell stress utilize a variety of molecular mechanisms to ensure mTORC1 inhibition during unfavourable conditions.

mTORC2: regulation and function

The regulation and function of mTORC2 remains poorly understood and thus represents an important area for future research. mTORC2 phosphorylates Akt, SGK1 (serum- and glucocorticoid-induced protein kinase 1) and PKC α on their hydrophobic motif sites (Ser⁴⁷³, Ser⁴²² and Ser⁶⁵⁷ respectively) [96,145,146]. Indeed, rictor^{-/-}, mSin1^{-/-} and mLST8/G β L^{-/-} MEFs (mouse embryonic fibroblasts) display significantly reduced Akt Ser⁴⁷³ phosphorylation [147,148]. On the basis of these substrates, mTORC2 probably controls cell proliferation, cell survival and cell metabolism. Additionally, in yeast and mammals, mTORC2 appears to modulate the actin cytoskeleton [42,149,150]. mTORC2 also promotes TM site phosphorylation on Akt (Thr⁴⁵⁰) and several PKCs (PKC α Thr⁶³⁸ and PKC β Thr⁶⁴¹) (directly or indirectly) [151,152], which enhances their stability and folding. In the case of Akt Thr⁴⁵⁰ phosphorylation, mTORC2 associates with ribosomes to promote co-translational TM site phosphorylation and stability of nascent Akt polypeptides [56]. As the mTORC1 substrate S6K1 and the mTORC2 substrates Akt, SGK1 and PKC α all belong to the AGC kinase family, an emerging theme in the mTOR field is that mTORC1 and mTORC2 phosphorylate AGC kinases. It is important to note, however, that additional kinases have been reported to mediate Akt HM site phosphorylation on Ser⁴⁷³, including DNA-PK (DNA-dependent protein kinase) [153], and quite recently the IKK-related kinases TBK1 and IKK ϵ [125-127], indicating that several upstream kinases co-operate to regulate this important survival kinase. As insulin/PI3K signalling promotes Akt Ser⁴⁷³ phosphorylation, and as pharmacological inhibition of PI3K reduces mTORC2 kinase activity *in vitro* [154], PI3K presumably lies upstream of mTORC2. Consistent with this idea, insulin/PI3K signalling in cultured adipocytes promotes mTOR phosphorylation (Ser¹²⁶¹) as part of mTORC2 [106]. Interestingly, the Tsc1-Tsc2 complex promotes rather than suppresses mTORC2 activity, the opposite to its effect on mTORC1, hinting that mTORC2 regulation may be quite different from that of mTORC1 [154,155]. As the mTORC2 substrates Akt, SGK1 and PKC α respond to different growth factors, it is likely that several types of growth factor signals converge on mTORC2.

CELLULAR SUBSTRATES AND FUNCTIONS OF THE mTORC1/S6K1 SIGNALLING AXIS

At the cellular level, mTORC1 functions as a critical regulator of translation initiation, the rate-limiting step in protein synthesis in which ribosomes are recruited to mRNA. Increased protein biosynthetic rates are thought to drive cell growth (an increase in cell mass and size), a requirement for cells to progress through the cell division cycle and proliferate (increase in number). Indeed, mTORC1 promotes cell growth and cell proliferation in response to anabolic cues via phosphorylation of S6K1 and 4EBP1, at least in part. Although it has been appreciated that the mTORC1-4EBP1 axis directly controls translation initiation, identifying substrates and functions of the mTORC1-S6K1 axis has proven more challenging.

For at least a decade after the discovery of S6K, rpS6 held ground as its one and only substrate. Since then, several S6K1 substrates have been identified that control protein production (Figure 3). Additional S6K1 substrates participate in

the transcriptional control of ribosome biogenesis, metabolism, lipid synthesis and adipocyte differentiation, as well as cell survival, DNA damage sensing and synaptic plasticity. An S6K1-mediated 'feedback loop' acts on several components of mTOR signalling networks, in some cases to down-regulate insulin signalling, which may contribute to insulin resistance during states of diabetes and obesity. However, detailed understanding of the functional significance of S6K1-mediated phosphorylation for many of these substrates remains limited. It is important to note that many S6K1 substrates {e.g. rpS6, eIF4B, eEF2K [eEF2 (eukaryotic elongation factor 2) kinase], CCT β [chaperonin containing TCP-1 (t-complex protein 1) β], BAD (Bcl-2/Bcl-X_L-antagonist, causing cell death), GSK3 (glycogen synthase kinase 3)} also serve as RSK substrates, illustrating the convergence of the mTORC1 and MAPK pathways in the common goal of regulating cell physiology.

Does the S6K–rpS6 axis promote mRNA TOP (terminal oligopyrimidine) translation?

S6K1-mediated phosphorylation of rpS6 was believed for quite a while to promote the translation of a class of ~90 transcripts known as TOP mRNAs that encode ribosomal proteins and translation factors [9]. The localization of rpS6 to the boundary between the 40S and 60S subunits in the mature ribosome and thus its potential to interact with mRNA, tRNA and translation initiation factors supported such a notion. In response to growth factors/mitogens or amino acids, the increased translational efficiency of TOP mRNAs correlated with S6K1 activation and rpS6 phosphorylation and occurred in a rapamycin-sensitive manner [156]. Moreover, expression of a rapamycin-resistant mutant of S6K1 (T389E) partially rescued the rapamycin-mediated suppression of TOP translation [157]. Thus increased TOP translation via the action of the mTORC1–S6K1–rpS6 axis was thought to prepare cells for a burst in protein synthesis. A series of subsequent experiments, however, were unable to provide further support for this long-standing model.

First, although inhibition of PI3K strongly inhibits the translational activation of TOP mRNAs in response to growth factors or amino acids, inhibition of mTORC1 with rapamycin only mediates a partial inhibitory effect, while causing complete dephosphorylation of S6K1 and rpS6 [158,159]. Secondly, genetic inactivation of S6K1 in the mouse has no effect on TOP translation; MEFs from these mice, however, still possess rpS6 phosphorylation, which led to the discovery of S6K2 as a second rpS6 kinase [14]. Thirdly, mitogens still promote TOP mRNA translation in a rapamycin-sensitive manner in MEFs lacking both S6K1 and S6K2 [19]. Thus neither of the two S6K genes is required for TOP translation. At this point, a role for rpS6 phosphorylation still remained possible, as rpS6 phosphorylation persisted on two (Ser²³⁵ and Ser²³⁶) of the five (Ser²³⁵, Ser²³⁶, Ser²⁴⁰, Ser²⁴⁴ and Ser²⁴⁷) mitogen-stimulated sites in double-null MEFs [19]. This observation led to the re-identification of RSK as a *bona fide* rpS6 kinase. One final experiment refuted the idea that rpS6 phosphorylation promotes TOP translation. MEFs isolated from mice bearing a genetic knockin of a rpS6 mutant containing alanine residue substitutions at all five mitogen-stimulated sites of phosphorylation (rpS6^{P-/-}) exhibit normal TOP translation and, unexpectedly, the rate of global protein synthesis is actually ~2.5-fold higher in these mice [160]. Further analysis confirmed that insulin promotes TOP translation via the PI3K–Tsc–Rheb–mTOR pathway in an S6K–rpS6-independent manner [161]. Knockdown of mTOR strongly reduces the translational efficiency of TOP mRNAs; knockdown of raptor or rictor, however, results in only a

modest decrease [161]. These data suggest that, although mTOR regulates TOP translation, it may do so independently of mTORC1 or mTORC2, an intriguing idea that will require further testing.

Protein biosynthesis

Protein biosynthesis represents a major cellular process controlled by mTORC1, which is co-ordinately regulated by the mTORC1–S6K1 and mTORC1–4EBP1 axes (Figure 4). The mTORC1–4EBP1 axis controls critical well-defined steps in the initiation of cap-dependent translation by assembling the eIF4F complex at the m⁷-GTP (7-methylguanosine) cap structure found at the 5'-end of mRNA transcripts. Significantly less is known regarding the role of the mTORC1–S6K1 axis in translational control, however (see the reviews by Ma and Blenis [10] and Hershey et al. [162] for greater detail). In the absence of mTORC1-activating stimuli (i.e. growth factors/mitogens, amino acids and energy), hypophosphorylated 4EBP1 binds to and represses eIF4E, which directly interacts with the 5'-cap [34]; additionally, a sub-pool of inactive S6K1 associates with the multi-subunit scaffold eIF3 [163] (Figure 4A). In response to mTORC1-activating stimuli, mTORC1 binds to eIF3, where it is well positioned to phosphorylate S6K1 (on Thr³⁸⁹) and 4EBP1 on several sites (e.g. Thr³⁷, Thr⁴⁶, Thr⁷⁰ and Ser⁶⁵). mTORC1-mediated 4EBP1 phosphorylation induces the dissociation of 4EBP1 from eIF4E and the dissociation of S6K1 from eIF3 (Figure 4B). As 4EBP1 and eIF4G (a modular scaffold) bind eIF4E in a mutually exclusive manner, 4EBP1 dissociation enables binding of eIF4G to eIF4E. Once bound to eIF4E, eIF4G recruits eIF4A, a helicase critical for unwinding inhibitory secondary structure in the 5'-untranslated region of mRNA. These events lead to formation of eIF4F, a complex composed of eIF4E, eIF4G and eIF4A, on the 5'-cap (Figure 4C). The assembled eIF4F complex then recruits the 40S ribosome and the ternary complex (composed of eIF2, Met-tRNA and GTP) to the 5'-cap to form the 48S translation pre-initiation complex (Figure 4D).

Upon mTORC1-mediated dissociation of S6K1 from eIF3, active S6K1 phosphorylates several substrates that function in translation initiation as well as other steps that drive protein production, including eIF4B [164,165], PDCD4 (programmed cell death 4) [166], SKAR (S6K1 Aly/REF-like substrate) [167,168], eEF2K [169], CCT β [170], CBP80 [171] and rpS6, a component of the 40S ribosome (Figures 3 and 4C). S6K1- (and RSK-) mediated phosphorylation of eIF4B (Ser⁴²²) induces the recruitment of eIF4B to eIF4A and eIF3 [163–165] (Figures 4C and 4D). eIF4B functions to enhance eIF4A helicase activity, thus alleviating inhibitory secondary structure in the 5'-untranslated region. S6K1-mediated phosphorylation of the eIF4A inhibitor PDCD4 (on Ser⁶⁷) further enhances eIF4A helicase activity. Phosphorylation of PDCD4, a tumour suppressor, promotes its recognition by the ubiquitination ligase SCF β -TRCP and thus its degradation by the proteasome [166]. SKAR, a nuclear mRNA-binding protein of the Aly/REF family, couples transcription with mRNA splicing and nuclear export by interacting with the exon junction complex, which binds to spliced mRNAs [168]. Upon growth-factor-stimulated activation, S6K1 but not S6K2 binds to and phosphorylates SKAR (Ser³⁸³/Ser³⁸⁵) to enhance the translational efficiency of newly spliced mRNA [167]. S6K1 (and RSK) also phosphorylates and inactivates eEF2K (Ser³⁶⁶), which phosphorylates and inactivates eEF2 [169]. Thus S6K1 augments the activity of eEF2, a protein that catalyses translocation (codon shifting) during translation elongation. S6K1 (and RSK) phosphorylates CCT β (Ser²⁶⁰), the β -subunit of chaperonin containing TCP-1 [170]. CCT β , a large




Figure 4 Model for initiation of cap-dependent translation by the mTORC1–4EBP1 and mTORC1–S6K1 axes

(A) In the absence of mTORC1-activating stimuli (i.e. growth factors/mitogens, amino acids and energy), hypophosphorylated 4EBP1 binds to eIF4E on the mRNA 5'-cap to suppress assembly of the pre-initiation complex. (B) In response to mTORC1-activating stimuli, mTORC1 docks to eIF3, localized at the 5'-cap, whereby it phosphorylates 4EBP1 and S6K1, inducing 4EBP1 release from eIF4E and S6K1 release from eIF3. (C) Dissociation of 4EBP1 enables eIF4G to dock to eIF4E, thus initiating assembly of the eIF4F complex (eIF4E, eIF4G and eIF4A). Upon release, S6K1 phosphorylates eIF4B, which induces eIF4B binding to eIF4A, an event that enhances eIF4A helicase activity. S6K also phosphorylates and inactivates PDCD4, which functions as an eIF4A inhibitor. (D) Assembly of these factors enables binding of the 40S ribosome and the ternary complex (eIF2, Met-tRNA and GTP) at the 5'-cap and thus formation of the pre-initiation complex (PIC) to initiate cap-dependent translation. See the main text for more details.

multi-subunit complex that interacts with ribosomes and nascent polypeptides, functions in protein folding. Knockdown of CCT β reduces cell proliferation, a phenotype rescued upon expression of a phospho-mimetic S260D but not a phospho-defective S260A mutant, thus linking CCT β phosphorylation by S6K1/RSK to

CCT β function [170]. Whether phosphorylation actually affects CCT β protein folding function will require further study. CBP80, together with CBP20, forms a heterodimeric complex that co-transcriptionally binds the 5'-cap and enhances mRNA splicing. The functional consequence of S6K1-mediated phosphorylation of CBP80 remains unknown [171]. Lastly, S6K1 phosphorylates rpS6 on several sites (Ser²³⁵, Ser²³⁶, Ser²⁴⁰ and Ser²⁴⁴), whereas RSK phosphorylates a subset of these sites (Ser²³⁵ and Ser²³⁶). It is important to note that the functional significance of rpS6 phosphorylation remains unclear [9,11]. Taken together, these data indicate that the mTORC1–4EBP1 and mTORC1–S6K1 axes control several diverse steps in protein biosynthesis.

Cell growth compared with cell proliferation

Cell growth

A plethora of studies in cell culture, flies and mice have revealed cell growth as a major cellular function of the mTORC1–S6K1 axis. The role of S6K in cell growth was first demonstrated with the finding that inactivation of dS6K in *D. melanogaster* results in severe developmental delay and lethality with a marked reduction in body and organ size in surviving animals [172]. Strikingly, this small body/organ phenotype results from a cell autonomous decrease in cell and organ size, without an effect on cell number [172]. Consistently, inhibition of mTORC1 and S6K via rapamycin treatment of cultured mammalian cells reduces cell size, and expression of rapamycin-resistant S6K1 alleles (T389E-D3E and T389E- Δ CT) rescues the rapamycin-induced decrease in cell size [75]. Moreover, acute knockdown of S6K1 with RNAi reduces cell size, and overexpression of S6K1 increases cell size [75,167,173]. As in flies, inactivation of S6K1 in the mouse reduces body and cell size, with pancreatic β -cells and myoblasts showing a prominent decrease in size [14,76,174]. The single knockout of S6K2 in the mouse actually results in larger animals, whereas S6K1^{-/-}/S6K2^{-/-} double-knockout animals are similar in size to single S6K1^{-/-} animals [19]. These data indicate that S6K1 but not S6K2 promotes organismal growth.

MEFs and myoblasts isolated from S6K1^{-/-}/S6K2^{-/-} double-knockout mice display a reduced cell size relative to wild-type controls, but a similar cell size relative to wild-type MEFs treated with mTOR catalytic inhibitors (e.g. Torin1 and PP242) [76,175]. Moreover, introduction of a constitutively active S6K1 (T389E-D3E) allele into double-knockout MEFs rescues this decrease in cell size in both the absence or presence of mTOR catalytic inhibitors [175]. These results reveal the S6Ks (most likely S6K1) as major downstream effectors of mTORC1-driven cell growth [175]. rpS6^{P-/-} MEFs also display a significantly reduced cell size compared with wild-type controls; moreover, rapamycin fails to decrease their size further [160]. These results reveal an important role for rpS6 phosphorylation in cell growth control. It is important to note, however, that S6K1 can promote cell growth independently of rpS6 phosphorylation, as small S6K1^{-/-} myotubes show normal levels of rpS6 phosphorylation (due to S6K2) [76]. The identification of these additional S6K1 substrates awaits future research. SKAR may represent one of these additional S6K1 effectors that controls cell growth, as its knockdown reduces cell size [167]. Lastly, the ability of the mTORC1–S6K1 axis to promote lipid biosynthesis as well as protein biosynthesis contributes to cell growth control, as knockdown of the lipogenic transcription factor SREBP (sterol-regulatory-element-binding protein) in flies or mammalian cells blunts the increase in cell size driven by PI3K/Akt signalling [176].

Cell proliferation

mTORC1 signalling promotes cell cycle progression and cell proliferation, although the molecular details underlying mTORC1-controlled proliferation remain poorly understood. Although several studies suggest that the mTORC1–S6K1 axis promotes cell cycle progression and cell proliferation, this notion remains somewhat controversial. On the one hand, overexpression of rapamycin-resistant S6K1 confers partial protection from rapamycin-inhibited G₁-/S-phase progression and cell proliferation, and acute knockdown of S6K1 with RNAi reduces G₁-/S-phase progression [76,177]. On the other hand, S6K1^{-/-}/S6K2^{-/-} double-knockout MEFs and myoblasts proceed through the cell cycle and proliferate at rates that are similar to wild-type cells [76,175]. How can this apparent paradox be explained? Perhaps S6K1 signalling is sufficient to promote cell proliferation when other mTOR effectors are inactive (as during rapamycin treatment) or perhaps other signalling systems compensate to fully rescue proliferation under chronic inactivation of S6K function (as during S6K1^{-/-}/S6K2^{-/-} knockout). Alternatively, rapamycin-resistant S6K1 could signal in a manner different from the wild-type kinase. To confuse matters more, rpS6^P^{-/-} MEFs proliferate faster than wild-type controls [160]. Other data suggest that overexpression of S6K1 and S6K2 confers a proliferative advantage on cells in culture [177–179]. Similar to S6K1, overexpression of rapamycin-resistant S6K2 (T388E) partially rescues rapamycin-inhibited G₁-/S-phase progression and cell proliferation [178]. Lastly, S6K2 may play a role in mitosis, as S6K2 but not S6K1 reportedly localizes to the centrosome, and S6K2 kinase activity peaks in G₂- and M-phases [180,181].

The mTORC1–4EBP1 axis appears to promote cell cycle progression and cell proliferation independent of the mTORC1–S6K1 axis. Overexpression of eIF4E under full serum conditions accelerates G₁-/S-phase progression and confers partial protection from rapamycin, whereas dominant inhibitory 4EBP1-F114A (TOS motif) or 4EBP1-AA (phosphorylation site-defective) mutants reduce G₁-/S-phase progression (by blunting mTORC1-mediated 4EBP1 phosphorylation and derepression) [177]. Additionally, MEFs lacking 4EBP1s display resistance to the inhibition of cell cycle progression and cell proliferation caused by mTOR catalytic inhibitors or raptor knockdown [175]. These data reveal the 4EBPs as major cellular effectors of mTORC1-driven cell cycle progression and cell proliferation [175].

Feedback signalling

The mTORC1–S6K1 axis participates in several feedback loops. Chronic mTORC1-mediated activation of S6K1, as in Tsc1^{-/-} or Tsc2^{-/-} cells that lack tumour-suppressive function, induces a state of cellular insulin resistance by a mechanism termed the ‘negative-feedback loop’ [182,183]. S6K1 signalling represses IRS-1 gene expression and directly phosphorylates IRS-1 on several inhibitory serine residues (i.e. Ser³⁰⁷ and Ser¹¹⁰¹ in humans) (Figure 3) [183–186]. In a co-operative manner, mTOR phosphorylates IRS-1 (Ser⁶³⁶/Ser⁶³⁹) [187]. IRS-1 serine phosphorylation induces IRS-1 degradation via the proteasome and thus uncouples PI3K from the insulin/IGF receptor, leading to reduced signalling to downstream PI3K effectors, including Akt and the Ras/MAPK pathway [184]. This negative-feedback loop may explain in part the insulin resistance common to obesity, a state of chronic nutrient overload and mTORC1 activation. The inactivation of this negative-feedback loop upon mTORC1 inhibition probably also explains in part why rapalogues (e.g. CCI-779 and RAD001) have failed to perform in anti-

cancer clinical trials as well as originally hoped [6,7]. Upon mTORC1 activation, S6K1 also participates in other feedback loops of unclear functional significance. S6K1 phosphorylates mTOR (Ser²⁴⁴⁸) [188,189] and rictor (Thr¹¹³⁵) [190–193]. As an mTOR S2448A mutant exhibits normal mTORC1 signalling, analysis of the mTOR Ser²⁴⁴⁸ phosphorylation state serves only as a read-out for S6K1 activity. Although one report suggested that S6K1-mediated phosphorylation of rictor Thr¹¹³⁵ suppresses mTORC2 signalling to Akt [190], other reports did not report such a phenotype [191–193]. In parallel to the mTORC1–S6K1 axis, recent work indicates that mTORC1 phosphorylates Grb10 to mediate negative feedback to insulin/IGF signalling [194,195].

Gene expression

Transcriptional profiling using microarrays has defined both positive and negative roles for mTORC1 signalling in control of gene expression [196–198]. These analyses have revealed mTORC1 signalling to control diverse metabolic genes. mTORC1 signalling up-regulates genes involved in lipid/sterol, nucleotide and protein synthesis, as well as genes involved in mitochondrial oxidative function, glycolysis and the pentose phosphate pathway; conversely, mTORC1 signalling down-regulates genes involved in nutrient breakdown and energy production [196,198]. At the molecular level, how mTORC1 signalling controls gene expression remains poorly understood. Signalling via the mTORC1–S6K1 axis promotes ribosome biogenesis by phosphorylating the rDNA (ribosomal DNA) transcription factor UBF (upstream binding factor) (either directly or indirectly), leading to the activation of 45S ribosomal gene transcription [199]. These data further underscore the dedicated role of mTORC1 in enhancing protein biosynthetic capacity. mTORC1 promotes the expression of genes involved in mitochondrial oxidative function by interacting with the transcription factor YY1 (Yin-Yang 1) [197]. mTORC1 binding to YY1 promotes interaction of YY1 with the co-activator PGC-1 α (peroxisome-proliferator-activated receptor γ coactivator-1 α). More recently, mTORC1 signalling was shown to modulate gene expression via the transcription factors HIF1 α , SREBP1 and SREBP2 [176,198]. Signalling via the mTORC1–4EBP1 axis enhances the translation of HIF1 α , which promotes expression of glycolytic genes; signalling via the mTORC1–S6K1 axis promotes the proteolytic processing of SREBP from an inactive precursor to an active transcription factor that rapidly shuttles into the nucleus, which promotes expression of genes in the oxidative pentose phosphate pathway as well as those involved in lipid and sterol biosynthesis [198]. Limited data suggest that S6K1 directly phosphorylates transcription factors to modulate their function. Serum stimulation of S6K1 was shown to phosphorylate and transactivate CREM τ (cAMP-response-element modulator τ) (Ser¹¹⁷) [200]. Additionally, S6K1 (and RSK) phosphorylates oestrogen receptor α (Ser¹⁶⁷), leading to its transcriptional activation, which may contribute to breast cancer progression (Figure 3) [201].

Other functions

The mTORC1–S6K1 axis has been linked to a variety of other cellular processes, including GSK3 regulation, adipocyte differentiation, cell survival, cell motility, DNA damage response and synaptic plasticity (Figure 3). In the absence of Tsc1/Tsc2 function, which results in high S6K1 activity but low Akt activity owing to feedback inhibition of PI3K/Akt, S6K1 (rather than Akt) phosphorylates and inactivates the multi-functional kinase

GSK3 [202]. mTORC1 signalling promotes discrete steps in adipocyte differentiation. The mTORC1–S6K1 axis enhances commitment of stem cells to early adipocyte progenitors [203], whereas mTORC1 signalling independent of S6K1 controls terminal adipocyte differentiation [204,205]. These steps in adipogenesis correlate with mTORC1-mediated increases in the expression of several transcription factors, further underscoring the role of mTORC1 signalling in control of gene expression. The mTORC1–S6K1 axis promotes cell survival via S6K1-mediated phosphorylation and inhibition of BAD (Ser¹³⁶), a pro-apoptotic BH3-only member of the Bcl-2 family [206]. Signalling through mTORC1 promotes cell motility via both the S6K1 and 4EBP1 axes [77]. The mTORC–S6K1 axis has also been reported to participate in the DNA damage response. Upon genotoxic stress, the p38 α MAPK pathway activates mTORC1–S6K1, whereby S6K1 binds to and phosphorylates Mdm2 (murine double minute 2) (Ser¹⁶³), blocking its nuclear import and ability to ubiquitinate the tumour suppressor protein p53 [207]. Thus p53 levels increase, resulting in cell cycle arrest or apoptosis. Lastly, the mTORC1–S6K1 axis participates in protein synthesis-dependent synaptic plasticity. In response to type I mGluR (metabotropic glutamate receptor) stimulation of mouse hippocampus, S6K1 phosphorylates FMRP (fragile X mental retardation protein), a dendritic RNA-binding protein that functions in translational repression and synaptic plasticity [208,209]. Thus S6K1-mediated phosphorylation of FMRP may modulate learning and memory.

THE mTORC1–S6K1 SIGNALLING AXIS IN PHYSIOLOGY AND DISEASE

Abundant evidence indicates important roles for mTORC1 in physiology and myriad disease states, including diabetes, obesity, cancer and benign tumour syndromes, organ hypertrophy, neurological disorders (e.g. autism spectrum disorders and Alzheimer's disease) and aging-related pathology [2,22,209]. These pathological responses probably stem from cellular effects of mTORC1 on protein and lipid synthesis, cell growth, cell proliferation and cellular metabolism. However, our understanding of the mTORC1 effectors that mediate these cellular and physiological responses remains in its infancy. In the present review, we will focus specifically on identified roles for the mTORC1–S6K1 axis in physiology and disease.

Diabetes: glucose homeostasis, insulin sensitivity and adipocyte metabolism

Deletion of S6K1 in the mouse results in a number of physiological alterations. In addition to having a smaller body and organ size, S6K1^{-/-} mice present with hypoinsulinaemia and glucose intolerance as a result of insufficient insulin production by pancreatic β -cells, which results, at least in part, from a reduction in β -cell size [174]. Strikingly, even though these mice are hypoinsulinaemic, they remain sensitive to insulin due to the elimination of the mTORC1–S6K1-mediated negative-feedback loop and inhibitory IRS-1 phosphorylation (described above). Consistently, the livers of wild-type and obese *db/db* (leptin receptor deficient) but not S6K1^{-/-} mice fed on a high-fat diet show increased IRS-1 phosphorylation (Ser¹¹⁰¹) and reduced PI3K/Akt signalling [186]. These results demonstrate that up-regulated signalling along the mTORC1–S6K1 axis contributes to insulin resistance *in vivo*. The phenotype of *rpS6*^{-/-} knockin mice mimics that of S6K1^{-/-} mice, as they display hypoinsulinaemia with impaired glucose tolerance owing to reduced insulin production by β -cells of reduced size

[160]. As these phenotypes reflect the aggregate response of all tissues, conditional knockout of S6K1 in specific tissues (adipose, muscle and liver) will be required to evaluate more precisely the roles of the mTORC1–S6K1 axis in peripheral control of glucose homeostasis and metabolism and how its dysregulation contributes to diabetes [22].

The mTORC1–S6K1 axis also controls adipocyte metabolism. S6K1^{-/-} mice possess fewer adipocytes owing to decreased differentiation of stem cells into adipogenic precursors (described above) [203]. Additionally, the mice store less fat than wild-type mice, owing to enhanced triacylglycerol (triglyceride) lipolysis, enhanced mitochondrial biogenesis and fatty acid β -oxidation, due to elevated AMPK activity and enhanced metabolic rate, as indicated by increased O₂ consumption [210,211]. Similarly, mTORC1 inhibition in cultured adipocytes via rapamycin or raptor knockdown enhances lipolysis, suppresses lipogenesis and thus reduces fat storage [212,213]. These phenotypes are consistent with the general anabolic role of mTORC1 in metabolism.

Obesity: body mass and energy balance

Whole-body S6K1^{-/-} mice display resistance to age- and diet-induced obesity, revealing a role for the mTORC1–S6K1 axis in control of body mass and energy balance [185]. Modulation of S6K1 activity, specifically in the mediobasal hypothalamus of rat brain, suggests a role for S6K1 in central control of feeding and metabolic responses that maintain energy balance [214]. Injection of adenoviruses expressing constitutively active S6K1 directly into the rat mediobasal hypothalamus decreases food intake and body weight; conversely, injection of adenoviruses expressing dominant-negative S6K1 produces opposite phenotypes [214]. These phenotypes mimic those resulting from mTORC1 activation effected by injection of leptin, an anorexigenic adipocyte-derived hormone, or leucine, an mTORC1-activating signal, into rat hypothalamus [215]. Thus, by these approaches, leptin signalling via mTORC1–S6K1 in the hypothalamus appears to modulate energy balance towards a leaner phenotype. It is important to note that the leaner phenotype produced by increased S6K1 signalling in hypothalamus opposes that produced by whole-body S6K1 knockout, a phenotype that indicates a role for S6K1 in promotion of body mass and adiposity. As many different types of neurons, each with specialized functions, compose the hypothalamus, the regulation and function of mTORC1–S6K1 signalling is probably unique within each type of neuron. Therefore the available data only assess aggregate responses [216]. Indeed, activation of the mTORC1 pathway by inactivation of Tsc1 in one class of neurons (anorexigenic pro-opiomelanocortin neurons) actually increases food intake and body weight, opposite to the results described above [217]. Clearly, more research will be required to unravel the complexities of energy balance control by the mTORC1–S6K1 axis.

Cancer: cell number control

Cancer results from aberrant control of fundamental cellular processes that ultimately control cell number, including cell proliferation, cell growth, cell survival and cell metabolism. The mTORC1 and mTORC2 pathways demonstrate frequent up-regulation in cancer, particularly under cellular conditions of heightened PI3K signalling due to oncogenic activation of PI3K or mutagenic inactivation of the lipid phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) [2,6,7]. As a result, mTOR signalling networks have emerged as attractive targets for novel therapeutic strategies to treat

cancer and various tumour syndromes (e.g. TSC). Indeed, the rapalogues CCI-779 (also known as temsirolimus) and RAD0001 (everolimus) were FDA-approved in 2007 and 2009 respectively to treat renal cell carcinoma. Overall, however, rapalogues have shown a rather disappointing efficacy in anti-cancer clinical trials, probably due to suppression of the mTORC1-mediated negative-feedback loop, which produces the undesired effect of increasing PI3K signalling. Additionally, it has recently become clear that rapamycin and rapalogues do not fully inhibit phosphorylation of all mTORC1 substrates (e.g. 4EBPs) [218]. Thus there exist rapamycin-sensitive (i.e. S6K) and rapamycin-insensitive (i.e. 4EBP1) mTORC1 substrates, which may explain in part the poor clinical efficacy of rapalogues as anti-cancer drugs. The recent development of ATP-competitive mTOR catalytic inhibitors (i.e. Torin1, PP242, Ku-0063794 and WAY600) that inhibit both mTORC1 and mTORC2 offer renewed optimism in clinical oncology [7].

To date, evidence for S6K1 and/or S6K2 signalling in mTOR-mediated tumorigenesis remains limited. S6K1 frequently shows overexpression in certain cancers, particularly breast cancer, due to 17q23 amplification of the *RPS6KB1* gene, and this phenotype correlates with poor prognosis [219]. More recent work suggests that S6K1 indeed contributes to tumorigenesis, although only in tissues bearing low S6K2 expression [220]. At the mRNA level, *S6K1* and *S6K2* show ubiquitous expression to comparable extents across diverse mouse tissues [220]. Although the S6K1 protein shows ubiquitous expression as well, S6K2 protein expression varies greatly in a tissue-specific manner, indicating that post-transcriptional mechanisms fine-tune the protein abundance of S6K2. Low S6K2 expression correlates with the ability of S6K1 deletion to impair tumorigenesis driven by heterozygous PTEN inactivation; in tissues bearing high S6K2 expression, deletion of S6K1 fails to blunt tumorigenesis. These results reveal a role for the mTORC1–S6K1 axis in tumorigenesis driven by PTEN inactivation, at least in tissues in which S6K2 fails to compensate for S6K1 function.

Hypertrophy: organ growth

In addition to promoting physiological cell and organ growth, mTORC1 signalling promotes pathological responses that induce organ hypertrophy, which describes increased organ mass and size primarily due to cellular hypertrophy rather than hyperplasia. In general, chronic organ hypertrophy correlates with impaired organ function and ultimately with patient morbidity and mortality. Indeed, mTORC1 inhibition with rapamycin in mice reduces load-induced cardiac hypertrophy and compensatory renal hypertrophy that occurs upon removal of a kidney (known as ‘uninephrectomy’) [221,222]. Renal hypertrophy represents an early event in the development of diabetic nephropathy, the leading cause of renal failure in the U.S.A. S6K1-knockout mice show resistance to uninephrectomy- and diabetes-induced renal hypertrophy, thus indicating that the mTORC1–S6K1 axis contributes to renal hypertrophy [223]. However, knockout of S6K1 as well as single S6K2 or double S6K1/S6K2 knockout fails to confer resistance to cardiac hypertrophy induced by physiological (exercise), pathological (aortic banding) or elevated PI3K signalling [224]. These results suggest that the mTORC1–S6K1 axis is not required for cardiac hypertrophy. S6K1 may be sufficient to promote cardiac hypertrophy, however, as transgenic overexpression of S6K1 in the heart induces modest hypertrophy [224]. Additionally, S6K1 contributes to airway smooth muscle hypertrophy, a structural change associated with asthma and airway hyper-responsiveness [173] and contributes to skeletal

muscle hypertrophy, as S6K1^{-/-} mice display skeletal muscle atrophy [76].

Learning and memory

Long-lasting synaptic plasticity and the formation of enduring memories requires protein synthesis [209]. Recent work suggests roles for mTORC1 in memory and learning. Although S6K1 or S6K2 knockout in mice has no effect on protein synthesis-dependent L-LTP [late-phase LTP (long-term potentiation)], S6K1, but not S6K2, knockout mice display impaired early-phase LTP and a diverse array of behavioural phenotypes associated with deficits in cognitive processing [225]. S6K2-knockout mice, however, indeed demonstrate memory impairment [225]. These findings suggest that the S6Ks, at least individually, are not required for the *de novo* protein synthesis that is important for enduring LTP. The mTORC1–S6K1 axis, however, is required for early phases of plasticity required for synaptic modifications and ultimately memory.

Aging

Caloric restriction and genetic inactivation of components within the insulin/IGF-1 signal transduction pathway increase lifespan and decrease age-related pathology in diverse model organisms [226]. Strikingly, genetic inactivation of TOR in yeast, worms and flies, which is thought to mimic nutrient restriction, increases longevity. Current thought suggests that TOR signalling promotes aging via mechanisms that may include increased generation of metabolic by-products and thus increased oxidative stress as well as impaired ability to maintain stem cell function [226]. Additionally, mTOR-mediated suppression of autophagy [via mTOR-mediated phosphorylation of ULK1/2 (unc-51-like kinase 1/2) and Atg13, in part] may promote aging due to a decreased ability to manage cellular damage [227–229]. Autophagy represents a cellular process whereby misfolded proteins and/or damaged organelles become sequestered within double-membrane vesicles for degradation in lysosomes. Indeed, many lifespan-extending strategies correlate with enhanced autophagy [228]. A role for mTORC1 in mammalian aging has been demonstrated with the finding that rapamycin-fed mice live longer than controls [230]. Moreover, knockout of S6K1 in mice or knockout of the single S6K gene in *C. elegans* (*rsk-1*) extends lifespan [231]. Strikingly, S6K1-knockout mice show decreased aging-related pathology, including bone, immune and motor dysfunction, and altered gene expression in a manner that resembles caloric restriction [231]. These results demonstrate a role for the mTORC1–S6K1 axis in longevity and aging-related pathology.

CONCLUDING COMMENTS

We have learned a great deal over the past 20 years regarding the cellular regulation and function of S6Ks within mTOR signalling networks; however, many questions remain. Although mTOR provides a critical activating input for S6Ks, other poorly understood phosphorylation events contribute to S6K regulation. It will be important in the future to identify the kinases for C-terminal S6K phosphorylation as well as the kinase(s) for the critical turn-motif site (Ser³⁷¹). The role that subcellular localization plays in the regulation and function of S6Ks needs to be better defined. Undiscovered S6K substrates probably exist. Identification of shared and unique substrates of S6K1 and S6K2 represents an important area for future research that

will provide improved understanding of the similarities and differences between S6K1 and S6K2 function. The development of a novel pharmacological inhibitor specific for S6K1, PF-4708671, will greatly facilitate the discovery of S6K1-specific cellular functions, similar to the use of rapamycin as a tool to identify mTORC1-controlled functions [232]. Our understanding of the role of the mTORC1–S6K1 axis in organismal physiology and pathophysiology remains in its infancy. Thus future research effort focused on elucidating the tissue-specific functions of S6K1 and S6K2 should prove informative and may identify diseases amenable to treatment with mTORC1- or S6K1-specific inhibitors. Lastly, the limited set of known mTOR substrates (i.e. S6K, 4EBP1, ULK1/2, Atg13, raptor, Akt, SGK, PKC and Grb10) and S6K1 substrates (Figure 3) probably does not account for the myriad cellular and physiological functions controlled by mTOR and S6K1 [1,3,195,194,233]. Thus the identification of the complete set of direct mTOR and S6K1/2 substrates remains an important area for future research. Recent MS-based phosphoproteomic screens in cultured cells identified a plethora of novel as well as known phosphorylation targets controlled directly by mTOR or indirectly via S6K1 or other downstream kinases [194,195]. Indeed, several of the reported S6K1 substrates described in the present review (Figure 3) were identified in these studies, including eIF4B, PDCD4, eEF2K, rpS6, Mdm2, BAD, GSK3 β , rictor, IRS and mTOR [194,195]. Hits from these screens probably represent novel mTOR and S6K substrates. The identification of mTOR and S6K targets will enable basic researchers to better define how mTOR controls physiology in S6K-dependent and -independent fashions.

ACKNOWLEDGEMENTS

We apologize to the many authors whose work we could not cite due to space restraints. We thank John Blenis for helpful comments.

FUNDING

Work in our laboratory is supported by the National Institutes of Health [grant number R01-DK-078135] and the American Heart Association (to D.C.F. and B.E.).

REFERENCES

- Foster, K. G. and Fingar, D. C. (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. *J. Biol. Chem.* **285**, 14071–14077
- Zoncu, R., Efeyan, A. and Sabatini, D. M. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat. Rev. Mol. Cell Biol.* **12**, 21–35
- Alessi, D. R., Pearce, L. R. and Garcia-Martinez, J. M. (2009) New insights into mTOR signaling: mTORC2 and beyond. *Sci. Signaling* **2**, pe27
- Augustine, J. J., Bodziak, K. A. and Hricik, D. E. (2007) Use of sirolimus in solid organ transplantation. *Drugs* **67**, 369–391
- Wessely, R. (2010) New drug-eluting stent concepts. *Nat. Rev. Cardiol.* **7**, 194–203
- Guertin, D. A. and Sabatini, D. M. (2009) The pharmacology of mTOR inhibition. *Sci. Signaling* **2**, pe24
- Liu, Q., Thoreen, C., Wang, J., Sabatini, D. and Gray, N. S. (2009) mTOR mediated anti-cancer drug discovery. *Drug Discovery Today Ther. Strateg.* **6**, 47–55
- Fenton, T. R. and Gout, I. T. (2011) Functions and regulation of the 70kDa ribosomal S6 kinases. *Int. J. Biochem. Cell Biol.* **43**, 47–59
- Meyuhas, O. and Drazan, A. (2009) Ribosomal protein S6 kinase from TOP mRNAs to cell size. *Prog. Mol. Biol. Transl. Sci.* **90**, 109–153
- Ma, X. M. and Blenis, J. (2009) Molecular mechanisms of mTOR-mediated translational control. *Nat. Rev. Mol. Cell Biol.* **10**, 307–318
- Meyuhas, O. (2008) Physiological roles of ribosomal protein S6: one of its kind. *Int. Rev. Cell Mol. Biol.* **268**, 1–37
- Banerjee, P., Ahmad, M. F., Grove, J. R., Kozlosky, C., Price, D. J. and Avruch, J. (1990) Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. *Proc. Natl. Acad. Sci. U.S.A.* **87**, 8550–8554
- Kozma, S. C., Ferrari, S., Bassand, P., Siegmund, M., Totty, N. and Thomas, G. (1990) Cloning of the mitogen-activated S6 kinase from the rat liver reveals an enzyme of the second messenger subfamily. *Proc. Natl. Acad. Sci. U.S.A.* **87**, 7365–7369
- Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G. and Kozma, S. C. (1998) Disruption of the p70^{S6K}/p85^{S6K} gene reveals a small mouse phenotype and a new functional S6 kinase. *EMBO J.* **17**, 6649–6659
- Lee-Fruman, K. K., Kuo, C. J., Lippincott, J., Terada, N. and Blenis, J. (1999) Characterization of S6K2, a novel kinase homologous to S6K1. *Oncogene* **18**, 5108–5114
- Gout, Y., Minami, T., Hara, K., Tsujishita, Y., Filonenko, V., Waterfield, M. D. and Yonezawa, K. (1998) Molecular cloning and characterization of a novel S6 kinase, p70 S6 kinase β containing a proline-rich region. *J. Biol. Chem.* **273**, 30061–30064
- Koh, H., Jee, K., Lee, B., Kim, J., Kim, D., Yun, Y. H., Kim, J. W., Choi, H.-S. and Chung, J. (1999) Cloning and characterization of a nuclear S6 kinase, S6 kinase-related kinase (SRK): A novel nuclear target of Akt. *Oncogene* **18**, 5115–5119
- Saitoh, M., ten Dijke, P., Miyazono, K. and Ichijo, H. (1998) Cloning and characterization of p70(S6K β) defines a novel family of p70 S6 kinases. *Biochem. Biophys. Res. Commun.* **253**, 470–476
- Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C. and Thomas, G. (2004) S6K1^{-/-}/S6K2^{-/-} mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveals a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol. Cell. Biol.* **24**, 3112–3124
- Gangloff, Y. G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J. F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G. and Kozma, S. C. (2004) Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. *Mol. Cell. Biol.* **24**, 9508–9516
- Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K. and Yamanaka, S. (2004) mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. *Mol. Cell. Biol.* **24**, 6710–6718
- Dann, S. G., Selvaraj, A. and Thomas, G. (2007) mTOR complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer. *Trends Mol. Med.* **13**, 252–259
- Sehgal, S. N., Baker, H. and Vezina, C. (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. *J. Antibiot.* **28**, 727–732
- Diamond, J. (2005) Collapse: How Societies Choose To Fail Or Succeed, pp. 79–119, Viking Penguin, New York
- Abraham, R. T. and Wiederrecht, G. J. (1996) Immunopharmacology of rapamycin. *Annu. Rev. Immunol.* **14**, 483–510
- Martel, R. R., Klicius, J. and Galet, S. (1977) Inhibition of the immune response by rapamycin, a new antifungal antibiotic. *Can. J. Physiol. Pharmacol.* **55**, 48–51
- Heitman, J., Movva, N. R. and Hall, M. N. (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science* **253**, 905–909
- Jones, S. W., Erikson, E., Blenis, J., Maller, J. L. and Erikson, R. L. (1988) A *Xenopus* ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. *Proc. Natl. Acad. Sci. U.S.A.* **85**, 3377–3381
- Carriere, A., Ray, H., Blenis, J. and Roux, P. P. (2008) The RSK factors of activating the Ras/MAPK signaling cascade. *Front. Biosci.* **13**, 4258–4275
- Chung, J., Kuo, C. J., Crabtree, G. R. and Blenis, J. (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70kD S6 protein kinases. *Cell* **69**, 1227–1236
- Kuo, C. J., Chung, J., Florentino, D. F., Flanagan, W. M., Blenis, J. and Crabtree, G. R. (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. *Nature* **358**, 70–73
- Price, D. J., Grove, J. R., Calvo, V., Avruch, J. and Bierer, B. E. (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. *Science* **257**, 973–977
- Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E. and Thomas, G. (1995) The principal target of rapamycin-induced p70S6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. *EMBO J.* **14**, 5279–5287
- Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N. and Sonenberg, N. (1996) Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. *EMBO J.* **15**, 658–664
- Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, Jr, J. C. and Abraham, R. T. (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. *Science* **277**, 99–101
- Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H. and Sabatini, D. M. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 1432–1437
- Isotani, S., Hara, K., Tokunaga, C., Inoue, H., Avruch, J. and Yonezawa, K. (1999) Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase α *in vitro*. *J. Biol. Chem.* **274**, 34493–34498

- 38 Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N. and Avruch, J. (1998) 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase *in vivo* and *in vitro*. *Curr. Biol.* **8**, 69–81
- 39 Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A. and Thomas, G. (1998) Phosphorylation and activation of p70s6k by PDK1. *Science* **279**, 707–710
- 40 Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J. and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. *Cell* **110**, 177–189
- 41 Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* **110**, 163–175
- 42 Loewith, R., Jacinto, E., Wullschlegel, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M. N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. *Mol. Cell* **10**, 457–468
- 43 Jacinto, E. and Lorberg, A. (2008) TOR regulation of AGC kinases in yeast and mammals. *Biochem. J.* **410**, 19–37
- 44 Pearce, L. R., Komander, D. and Alessi, D. R. (2010) The nuts and bolts of AGC protein kinases. *Nat. Rev. Mol. Cell Biol.* **11**, 9–22
- 45 Grove, J. R., Banerjee, P., Balasubramanyam, A., Coffey, P. J., Price, D. J., Avruch, J. and Woodgett, J. R. (1991) Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. *Mol. Cell. Biol.* **11**, 5541–5550
- 46 Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D. and Krainer, A. R. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. *Nat. Struct. Mol. Biol.* **14**, 185–193
- 47 Kim, D., Akcakamat, A., Singh, G., Sharma, C. and Meric-Bernstam, F. (2009) Regulation and localization of ribosomal protein S6 kinase 1 isoforms. *Growth Factors* **27**, 12–21
- 48 Chou, M. M. and Blenis, J. (1996) The 70kD S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. *Cell* **85**, 573–583
- 49 Romanelli, A., Martin, K. A., Toker, A. and Blenis, J. (1999) p70 S6 kinase is regulated by protein kinase C ζ and participates in a phosphoinositide 3-kinase-regulated signalling complex. *Mol. Cell. Biol.* **19**, 2921–2928
- 50 Weng, Q. P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J. and Avruch, J. (1998) Regulation of the p70 S6 kinase by phosphorylation *in vivo*. Analysis using site-specific antiphosphopeptide antibodies. *J. Biol. Chem.* **273**, 16621–16629
- 51 Moser, B. A., Dennis, P. B., Pullen, N., Pearson, R. B., Williamson, N. A., Wettenhall, R. E., Kozma, S. C. and Thomas, G. (1997) Dual requirement for a newly identified phosphorylation site in p70s6k. *Mol. Cell. Biol.* **17**, 5648–5655
- 52 Han, J. W., Pearson, R. B., Dennis, P. B. and Thomas, G. (1995) Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70S6k by inducing dephosphorylation of the same subset of sites. *J. Biol. Chem.* **270**, 21396–21403
- 53 Mukhopadhyay, N. K., Price, D. J., Kyriakis, J. M., Pelech, S., Sanghera, J. and Avruch, J. (1992) An array of insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the p70 S6 kinase. *J. Biol. Chem.* **267**, 3325–3335
- 54 Ferrari, S., Bannwarth, W., Morley, S. J., Totty, N. F. and Thomas, G. (1992) Activation of p70s6k is associated with phosphorylation of four clustered sites displaying Ser/Thr motifs. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 7282–7286
- 55 Keshwani, M. M., von Daake, S., Newton, A. C., Harris, T. K. and Taylor, S. S. (2011) Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1). *J. Biol. Chem.* **286**, 23552–23558
- 56 Oh, W. J., Wu, C. C., Kim, S. J., Facchinetti, V., Julien, L. A., Finlan, M., Roux, P. P., Su, B. and Jacinto, E. (2010) mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. *EMBO J.* **29**, 3939–3951
- 57 Price, D. J., Mukhopadhyay, N. K. and Avruch, J. (1991) Insulin-activated protein kinases phosphorylate a pseudosubstrate synthetic peptide inhibitor of the p70 S6 kinase. *J. Biol. Chem.* **266**, 16281–16284
- 58 Ferrari, S., Pearson, R. B., Siegmund, M., Kozma, S. C. and Thomas, G. (1993) The immunosuppressant rapamycin induces inactivation of p70S6k through dephosphorylation of a novel set of sites. *J. Biol. Chem.* **268**, 16091–16094
- 59 Schalm, S. S. and Blenis, J. (2002) Identification of a conserved motif required for mTOR signaling. *Curr. Biol.* **12**, 632–639
- 60 Dennis, P. B., Pullen, N., Pearson, R. B., Kozma, S. C. and Thomas, G. (1998) Phosphorylation sites in the autoinhibitory domain participate in p70(s6k) activation loop phosphorylation. *J. Biol. Chem.* **273**, 14845–14852
- 61 Cheatham, L., Monfar, M., Chou, M. M. and Blenis, J. (1995) Structural and functional analysis of p70 S6 kinase. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 11696–11700
- 62 Weng, Q., Andrabi, K., Kozlowski, M. T., Grove, J. R. and Avruch, J. (1995) Multiple independent inputs are required for activation of the p70 S6 kinase. *Mol. Cell. Biol.* **15**, 2333–2340
- 63 Dennis, P. B., Pullen, N., Kozma, S. C. and Thomas, G. (1996) The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. *Mol. Cell Biol.* **16**, 6242–6251
- 64 Schalm, S. S., Fingar, D. C., Sabatini, D. M. and Blenis, J. (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. *Curr. Biol.* **13**, 797–806
- 65 Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K., Hara, K., Tanaka, N., Avruch, J. and Yonezawa, K. (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. *J. Biol. Chem.* **278**, 15461–15464
- 66 Schalm, S. S., Tee, A. R. and Blenis, J. (2005) Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. *J. Biol. Chem.* **280**, 11101–11106
- 67 Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B. and Cohen, P. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B α . *Curr. Biol.* **7**, 261–269
- 68 Williams, M. R., Arthur, J. S., Balendran, A., van der Kaay, J., Poli, V., Cohen, P. and Alessi, D. R. (2000) The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. *Curr. Biol.* **10**, 439–448
- 69 Collins, B. J., Deak, M., Arthur, J. S., Armit, L. J. and Alessi, D. R. (2003) *In vivo* role of the PIF-binding docking site of PDK1 defined by knock-in mutation. *EMBO J.* **22**, 4202–4211
- 70 McManus, E. J., Collins, B. J., Ashby, P. R., Prescott, A. R., Murray-Tait, V., Armit, L. J., Arthur, J. S. and Alessi, D. R. (2004) The *in vivo* role of PtdIns(3,4,5)P $_3$ binding to PDK1 PH domain defined by knockin mutation. *EMBO J.* **23**, 2071–2082
- 71 Saitoh, M., Pullen, N., Brennan, P., Cantrell, D., Dennis, P. B. and Thomas, G. (2002) Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. *J. Biol. Chem.* **277**, 20104–20112
- 72 Sunami, T., Byrne, N., Diehl, R. E., Funabashi, K., Hall, D. L., Ikuta, M., Patel, S. B., Shipman, J. M., Smith, R. F., Takahashi, I. et al. (2010) Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. *J. Biol. Chem.* **285**, 4587–4594
- 73 Frodin, M., Antal, T. L., Dummler, B. A., Jensen, C. J., Deak, M., Gammeltoft, S. and Biondi, R. M. (2002) A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. *EMBO J.* **21**, 5396–5407
- 74 Romanelli, A., Dreisbach, V. C. and Blenis, J. (2002) Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr³⁸⁹ in p70 S6 kinase 1. *J. Biol. Chem.* **277**, 40281–40289
- 75 Fingar, D. C., Salama, S., Tsou, C., Harlow, E. and Blenis, J. (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. *Genes Dev.* **16**, 1472–1487
- 76 Ohanna, M., Sobering, A. K., Lapointe, T., Lorenzo, L., Praud, C., Petroulakis, E., Sonenberg, N., Kelly, P. A., Sotiropoulos, A. and Pende, M. (2005) Atrophy of S6K1^{-/-} skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. *Nat. Cell Biol.* **7**, 286–294
- 77 Liu, L., Li, F., Cardelli, J. A., Martin, K. A., Blenis, J. and Huang, S. (2006) Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. *Oncogene* **25**, 7029–7040
- 78 Ali, S. M. and Sabatini, D. M. (2005) Structure of S6 kinase 1 determines whether raptor-mTOR or Rictor-mTOR phosphorylates its hydrophobic motif site. *J. Biol. Chem.* **280**, 19445–19448
- 79 Duvel, K. and Broach, J. R. (2004) The role of phosphatases in TOR signaling in yeast. *Curr. Top. Microbiol. Immunol.* **279**, 19–38
- 80 Westphal, R. S., Coffee, Jr, R. L., Marotta, A., Pelech, S. L. and Wadzinski, B. E. (1999) Identification of kinase-phosphatase signaling modules composed of p70 S6 kinase-protein phosphatase 2A (PP2A) and p21-activated kinase-PP2A. *J. Biol. Chem.* **274**, 687–692
- 81 Peterson, R. T., Desai, B. N., Hardwick, J. S. and Schreiber, S. L. (1999) Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 4438–4442
- 82 Hahn, K., Miranda, M., Francis, V. A., Vendrell, J., Zorzano, A. and Teleman, A. A. (2010) PP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation. *Cell Metab.* **11**, 438–444
- 83 Fenton, T. R., Gwalter, J., Ericsson, J. and Gout, I. T. (2010) Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases *in vitro* and *in vivo*. *Int. J. Biochem. Cell Biol.* **42**, 359–366
- 84 Fenton, T. R., Gwalter, J., Cramer, R. and Gout, I. T. (2010) S6K1 is acetylated on lysine 516 in response to growth factor stimulation. *Biochem. Biophys. Res. Commun.* **398**, 400–405
- 85 Wang, M. L., Panasyuk, G., Gwalter, J., Nemazany, I., Fenton, T., Filonenko, V. and Gout, I. (2008) Regulation of ribosomal protein S6 kinases by ubiquitination. *Biochem. Biophys. Res. Commun.* **369**, 382–387
- 86 Gwalter, J., Wang, M. L. and Gout, I. (2009) The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase. *Int. J. Biochem. Cell Biol.* **41**, 828–833

- 87 Panasyuk, G., Nemazany, I., Filonenko, V. and Gout, I. (2008) Ribosomal protein S6 kinase 1 interacts with and is ubiquitinated by ubiquitin ligase ROC1. *Biochem. Biophys. Res. Commun.* **369**, 339–343
- 88 Wu, Y. T., Ouyang, W., Lazorchak, A. S., Liu, D., Shen, H. M. and Su, B. (2011) mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. *J. Biol. Chem.* **286**, 14190–14198
- 89 Kim, J. E. and Chen, J. (2000) Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 14340–14345
- 90 Valovka, T., Verdier, F., Cramer, R., Zhyvolou, A., Fenton, T., Rebholz, H., Wang, M. L., Gzhogotsky, M., Lutsyk, A., Matsuka, G. et al. (2003) Protein kinase C phosphorylates ribosomal protein S6 kinase β II and regulates its subcellular localization. *Mol. Cell. Biol.* **23**, 852–863
- 91 Martin, K. A., Schalm, S. S., Richardson, C., Romanelli, A., Keon, K. L. and Blenis, J. (2001) Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. *J. Biol. Chem.* **276**, 7884–7891
- 92 Martin, K. A., Schalm, S. S., Romanelli, A., Keon, K. L. and Blenis, J. (2001) Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein extracellular signal-regulated kinase kinase-regulated phosphorylation. *J. Biol. Chem.* **276**, 7892–7898
- 93 Phin, S., Kupferwasser, D., Lam, J. and Lee-Fruman, K. K. (2003) Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1. *Biochem. J.* **373**, 583–591
- 94 Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L. and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol. Cell* **22**, 159–168
- 95 Sengupta, S., Peterson, T. R. and Sabatini, D. M. (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. *Mol. Cell* **40**, 310–322
- 96 Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* **307**, 1098–1101
- 97 Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. and Cantley, L. C. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/Akt pathway. *Mol. Cell* **10**, 151–162
- 98 Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A. and Sabatini, D. M. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. *Mol. Cell* **25**, 903–915
- 99 van der Haar, E., Lee, S. I., Bandhakavi, S., Griffin, T. J. and Kim, D. H. (2007) Insulin signaling to mTOR mediated by the AKT/PKB substrate PRAS40. *Nat. Cell Biol.* **9**, 316–323
- 100 Huang, J. and Manning, B. D. (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. *Biochem. J.* **412**, 179–190
- 101 Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. and Blenis, J. (2003) Tuberous sclerosis complex gene products, Tuberlin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr. Biol.* **13**, 1259–1268
- 102 Inoki, K., Li, Y., Xu, T. and Guan, K. L. (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev.* **17**, 1829–1834
- 103 Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. and Avruch, J. (2005) Rheb binds and regulates the mTOR kinase. *Curr. Biol.* **15**, 702–713
- 104 Sato, T., Nakashima, A., Guo, L. and Tamanoi, F. (2009) Specific activation of mTORC1 by Rheb G-protein *in vitro* involves enhanced recruitment of its substrate protein. *J. Biol. Chem.* **284**, 12783–12791
- 105 Soliman, G. A., Acosta-Jaquez, H. A., Dunlop, E. A., Ekim, B., Maj, N. E., Tee, A. R. and Fingar, D. C. (2010) mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. *J. Biol. Chem.* **285**, 7866–7879
- 106 Acosta-Jaquez, H. A., Keller, J. A., Foster, K. G., Ekim, B., Soliman, G. A., Feener, E. P., Ballif, B. A. and Fingar, D. C. (2009) Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. *Mol. Cell. Biol.* **29**, 4308–4324
- 107 Ekim, B., Magnuson, B., Acosta-Jaquez, H. A., Keller, J. A., Feener, E. P. and Fingar, D. C. (2011) mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. *Mol. Cell. Biol.* **31**, 2787–2801
- 108 Foster, K. G., Acosta-Jaquez, H. A., Romeo, Y., Ekim, B., Soliman, G. A., Carriere, A., Roux, P. P., Ballif, B. A. and Fingar, D. C. (2010) Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. *J. Biol. Chem.* **285**, 80–94
- 109 Wang, L., Lawrence, Jr, J. C., Sturgill, T. W. and Harris, T. E. (2009) Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. *J. Biol. Chem.* **284**, 14693–14697
- 110 Carriere, A., Cargnello, M., Julien, L. A., Gao, H., Bonnell, E., Thibault, P. and Roux, P. P. (2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. *Curr. Biol.* **18**, 1269–1277
- 111 Carriere, A., Romeo, Y., Acosta-Jaquez, H. A., Moreau, J., Bonnell, E., Thibault, P., Fingar, D. C. and Roux, P. P. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). *J. Biol. Chem.* **286**, 567–577
- 112 Oshiro, N., Takahashi, R., Yoshino, K., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J. et al. (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. *J. Biol. Chem.* **282**, 20329–20339
- 113 Wang, L., Harris, T. E., Roth, R. A. and Lawrence, Jr, J. C. (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. *J. Biol. Chem.* **282**, 20036–20044
- 114 Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S. and Sabatini, D. M. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* **137**, 873–886
- 115 Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. and Pandolfi, P. P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell* **121**, 179–193
- 116 Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P. and Blenis, J. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 13489–13494
- 117 Fang, Y., Vilella-Bach, M., Bachmann, R., Flanagan, A. and Chen, J. (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. *Science* **294**, 1942–1945
- 118 Sun, Y., Fang, Y., Yoon, M. S., Zhang, C., Rocco, M., Zwartkruis, F. J., Armstrong, M., Brown, H. A. and Chen, J. (2008) Phospholipase D1 is an effector of Rheb in the mTOR pathway. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 8286–8291
- 119 Toschi, A., Lee, E., Xu, L., Garcia, A., Gadir, N. and Foster, D. A. (2009) Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. *Mol. Cell. Biol.* **29**, 1411–1420
- 120 Lee, D. F., Kuo, H. P., Chen, C. T., Hsu, J. M., Chou, C. K., Wei, Y., Sun, H. L., Li, L. Y., Ping, B., Huang, W. C. et al. (2007) IKK β suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* **130**, 440–455
- 121 Lee, D. F., Kuo, H. P., Chen, C. T., Wei, Y., Chou, C. K., Hung, J. Y., Yen, C. J. and Hung, M. C. (2008) IKK β suppression of TSC1 function links the mTOR pathway with insulin resistance. *Int. J. Mol. Med.* **22**, 633–638
- 122 Dan, H. C., Adli, M. and Baldwin, A. S. (2007) Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I κ B kinase α . *Cancer Res.* **67**, 6263–6269
- 123 Dan, H. C. and Baldwin, A. S. (2008) Differential involvement of I κ B kinases α and β in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. *J. Immunol.* **180**, 7582–7589
- 124 Dan, H. C., Cooper, M. J., Cogswell, P. C., Duncan, J. A., Ting, J. P. and Baldwin, A. S. (2008) Akt-dependent regulation of NF- κ B is controlled by mTOR and Raptor in association with IKK. *Genes Dev.* **22**, 1490–1500
- 125 Xie, X., Zhang, D., Zhao, B., Lu, M. K., You, M., Condorelli, G., Wang, C. Y. and Guan, K. L. (2011) I κ B kinase ϵ and TANK-binding kinase 1 activate AKT by direct phosphorylation. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 6474–6479
- 126 Joung, S. M., Park, Z. Y., Rani, S., Takeuchi, O., Akira, S. and Lee, J. Y. (2011) Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. *J. Immunol.* **186**, 499–507
- 127 Ou, Y. H., Torres, M., Ram, R., Formstecher, E., Roland, C., Cheng, T., Brekken, R., Wurz, R., Tasker, A., Pulverino, T. et al. (2011) TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. *Mol. Cell* **41**, 458–470
- 128 Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J. and Proud, C. G. (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. *J. Biol. Chem.* **280**, 18717–18727
- 129 Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C. et al. (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. *Cell* **136**, 521–534
- 130 Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L. and Sabatini, D. M. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* **320**, 1496–1501
- 131 Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P. and Guan, K. L. (2008) Regulation of TORC1 by Rag GTPases in nutrient response. *Nat. Cell Biol.* **10**, 935–945
- 132 Sancak, Y., Bar-Peled, L., Zoucu, R., Markhard, A. L., Nada, S. and Sabatini, D. M. (2010) Regulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* **141**, 290–303
- 133 Nada, S., Hondo, A., Kasai, A., Koike, M., Saito, K., Uchiyama, Y. and Okada, M. (2009) The novel lipid raft adaptor p18 controls endosome dynamics by anchoring the MEK-ERK pathway to late endosomes. *EMBO J.* **28**, 477–489
- 134 Flinn, R. J., Yan, Y., Goswami, S., Parker, P. J. and Backer, J. M. (2010) The late endosome is essential for mTORC1 signaling. *Mol. Biol. Cell* **21**, 833–841
- 135 Sacci, A., Cantley, L. C. and Carpenter, C. L. (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. *Mol. Cell* **42**, 50–61
- 136 Shackelford, D. B. and Shaw, R. J. (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat. Rev. Cancer* **9**, 563–575

- 137 Inoki, K., Zhu, T. and Guan, K. L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. *Cell* **115**, 577–590
- 138 Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E. and Shaw, R. J. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol. Cell* **30**, 214–226
- 139 Zheng, M., Wang, Y. H., Wu, X. N., Wu, S. Q., Lu, B. J., Dong, M. Q., Zhang, H., Sun, P., Lin, S. C., Guan, K. L. and Han, J. (2011) Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. *Nat. Cell Biol.* **13**, 263–272
- 140 Brugarolas, J., Lei, K., Hurler, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W. and Kaelin, Jr, W. G. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. *Genes Dev.* **18**, 2893–2904
- 141 Sofer, A., Lei, K., Johannessen, C. M. and Ellisen, L. W. (2005) Regulation of mTOR and cell growth in response to energy stress by REDD1. *Mol. Cell Biol.* **25**, 5834–5845
- 142 DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D. and Ellisen, L. W. (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. *Genes Dev.* **22**, 239–251
- 143 Budanov, A. V. and Karin, M. (2008) p53 target genes *sestrin1* and *sestrin2* connect genotoxic stress and mTOR signaling. *Cell* **134**, 451–460
- 144 Whitney, M. L., Jefferson, L. S. and Kimball, S. R. (2009) ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. *Biochem. Biophys. Res. Commun.* **379**, 451–455
- 145 Hresko, R. C. and Mueckler, M. (2005) mTOR-RICTOR is the Ser⁴⁷³ kinase for Akt/protein kinase B in 3T3-L1 adipocytes. *J. Biol. Chem.* **280**, 40406–40416
- 146 Garcia-Martinez, J. M. and Alessi, D. R. (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *Biochem. J.* **416**, 375–385
- 147 Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC α , but not S6K1. *Dev. Cell* **11**, 859–871
- 148 Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. *Cell* **127**, 125–137
- 149 Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr. Biol.* **14**, 1296–1302
- 150 Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A. and Hall, M. N. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat. Cell Biol.* **6**, 1122–1128
- 151 Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q. et al. (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. *EMBO J.* **27**, 1932–1943
- 152 Ikenoue, T., Inoki, K., Yang, Q., Zhou, X. and Guan, K. L. (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. *EMBO J.* **27**, 1919–1931
- 153 Feng, J., Park, J., Cron, P., Hess, D. and Hemmings, B. A. (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. *J. Biol. Chem.* **279**, 41189–41196
- 154 Huang, J., Dibble, C. C., Matsuzaki, M. and Manning, B. D. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. *Mol. Cell Biol.* **28**, 4104–4115
- 155 Huang, J., Wu, S., Wu, C. L. and Manning, B. D. (2009) Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. *Cancer Res.* **69**, 6107–6114
- 156 Jefferies, H. B. J., Reinhard, C., Kozma, S. C. and Thomas, G. (1994) Rapamycin selectively represses translation of the “polypyrimidine tract” mRNA family. *Proc. Natl. Acad. Sci. U.S.A.* **91**, 4441–4445
- 157 Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B. and Thomas, G. (1997) Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70S6k. *EMBO J.* **16**, 3693–3704
- 158 Stolovich, M., Tang, H., Hornstein, E., Levy, G., Cohen, R., Bae, S. S., Birnbaum, M. J. and Meyuhas, O. (2002) Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. *Mol. Cell Biol.* **22**, 8101–8113
- 159 Tang, H., Hornstein, E., Stolovich, M., Levy, G., Livingstone, M., Templeton, D., Avruch, J. and Meyuhas, O. (2001) Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. *Mol. Cell Biol.* **21**, 8671–8683
- 160 Ruvinsky, I., Sharon, N., Lerer, T., Cohen, H., Stolovich-Rain, M., Nir, T., Dor, Y., Zisman, P. and Meyuhas, O. (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. *Genes Dev.* **19**, 2199–2211
- 161 Patursky-Polischuk, I., Stolovich-Rain, M., Hausner-Hanochi, M., Kasir, J., Cybulski, N., Avruch, J., Ruegg, M. A., Hall, M. N. and Meyuhas, O. (2009) The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner. *Mol. Cell Biol.* **29**, 640–649
- 162 Hershey, J. W. (2010) Regulation of protein synthesis and the role of eIF3 in cancer. *Braz. J. Med. Biol. Res.* **43**, 920–930
- 163 Holz, M. K., Ballif, B. A., Gygi, S. P. and Blenis, J. (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell* **123**, 569–580
- 164 Raught, B., Peiretti, F., Gingras, A. C., Livingstone, M., Shahbazian, D., Mayeur, G. L., Polakiewicz, R. D., Sonenberg, N. and Hershey, J. W. (2004) Phosphorylation of eukaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. *EMBO J.* **23**, 1761–1769
- 165 Shahbazian, D., Roux, P. P., Mieulet, V., Cohen, M. S., Raught, B., Taunton, J., Hershey, J. W., Blenis, J., Pende, M. and Sonenberg, N. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. *EMBO J.* **25**, 2781–2791
- 166 Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E. and Pagano, M. (2006) S6K1- and β TRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. *Science* **314**, 467–471
- 167 Richardson, C. J., Broenstrup, M., Fingar, D. C., Julich, K., Ballif, B. A., Gygi, S. and Blenis, J. (2004) SKAR is a specific target of S6 kinase 1 in cell growth control. *Curr. Biol.* **14**, 1540–1549
- 168 Ma, X. M., Yoon, S. O., Richardson, C. J., Julich, K. and Blenis, J. (2008) SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. *Cell* **133**, 303–313
- 169 Wang, X., Li, W., Williams, M., Terada, N., Alessi, D. R. and Proud, C. G. (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. *EMBO J.* **20**, 4370–4379
- 170 Abe, Y., Yoon, S. O., Kubota, K., Mendoza, M. C., Gygi, S. P. and Blenis, J. (2009) p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. *J. Biol. Chem.* **284**, 14939–14948
- 171 Wilson, K. F., Wu, W. J. and Cerione, R. A. (2000) Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex. *J. Biol. Chem.* **275**, 37307–37310
- 172 Montagne, J., Stewart, M. J., Stocker, H., Hafen, E., Kozma, S. C. and Thomas, G. (1999) *Drosophila* S6 kinase: a regulator of cell size. *Science* **285**, 2126–2129
- 173 Deng, H., Hershenson, M. B., Lei, J., Bitar, K. N., Fingar, D. C., Solway, J. and Bentley, J. K. (2010) p70 Ribosomal S6 kinase is required for airway smooth muscle cell size enlargement but not increased contractile protein expression. *Am. J. Respir. Cell Mol. Biol.* **42**, 744–752
- 174 Pende, M., Kozma, S. C., Jaquet, M., Oorschot, V., Burcelin, R., Le Marchand-Brustel, Y., Klumperman, J., Thorens, B. and Thomas, G. (2000) Hypoinsulinaemia, glucose intolerance and diminished β -cell size in S6K1-deficient mice. *Nature* **408**, 994–997
- 175 Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M. and Sonenberg, N. (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. *Cancer Res.* **67**, 10804–10812
- 176 Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leever, S., Griffiths, J. R., Chung, Y. L. and Schulze, A. (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab.* **8**, 224–236
- 177 Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C. and Blenis, J. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Mol. Cell Biol.* **24**, 200–216
- 178 Cruz, R., Hedden, L., Boyer, D., Kharas, M. G., Fruman, D. A. and Lee-Fruman, K. K. (2005) S6 kinase 2 potentiates interleukin-3-driven cell proliferation. *J. Leukocyte Biol.* **78**, 1378–1385
- 179 Goh, E. T., Pardo, O. E., Michael, N., Niewiarowski, A., Totty, N., Volkova, D., Tsaneva, I. R., Seckl, M. J. and Gout, I. (2010) Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway. *J. Biol. Chem.* **285**, 17065–17076
- 180 Rossi, R., Pester, J. M., McDowell, M., Soza, S., Montecucco, A. and Lee-Fruman, K. K. (2007) Identification of S6K2 as a centrosome-located kinase. *FEBS Lett.* **581**, 4058–4064

- 181 Boyer, D., Quintanilla, R. and Lee-Fruman, K. K. (2008) Regulation of catalytic activity of S6 kinase 2 during cell cycle. *Mol. Cell. Biochem.* **307**, 59–64
- 182 Shah, O. J., Wang, Z. and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Curr. Biol.* **14**, 1650–1656
- 183 Harrington, L. S., Findlay, G. M., Gray, A., Tolkaheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R. et al. (2004) The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J. Cell Biol.* **166**, 213–223
- 184 Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C. et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. *J. Clin. Invest.* **118**, 3065–3074
- 185 Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J. and Thomas, G. (2004) Absence of S6K1 protects against age and diet-induced obesity while enhancing insulin sensitivity. *Nature* **431**, 200–205
- 186 Tremblay, F., Brule, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G. and Marette, A. (2007) Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 14056–14061
- 187 Ozes, O. N., Akca, H., Mayo, L. D., Gustin, J. A., Maehama, T., Dixon, J. E. and Donner, D. B. (2001) A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 4640–4645
- 188 Holz, M. K. and Blenis, J. (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. *J. Biol. Chem.* **280**, 26089–26093
- 189 Chiang, G. G. and Abraham, R. T. (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. *J. Biol. Chem.* **280**, 25485–25490
- 190 Dibble, C. C., Asara, J. M. and Manning, B. D. (2009) Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. *Mol. Cell. Biol.* **29**, 5657–5670
- 191 Julien, L. A., Carriere, A., Moreau, J. and Roux, P. P. (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. *Mol. Cell. Biol.* **30**, 908–921
- 192 Treins, C., Warne, P. H., Magnuson, M. A., Pende, M. and Downward, J. (2010) Rictor is a novel target of p70 S6 kinase-1. *Oncogene* **29**, 1003–1016
- 193 Boulbes, D., Chen, C. H., Shaikhenov, T., Agarwal, N. K., Peterson, T. R., Addona, T. A., Keshishian, H., Carr, S. A., Magnuson, M. A., Sabatini, D. M. and Sarbassov, D. D. (2010) Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. *Mol. Cancer Res.* **8**, 896–906
- 194 Yu, Y., Yoon, S. O., Poulgiannis, G., Yang, Q., Ma, X. M., Villen, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P. and Blenis, J. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science* **332**, 1322–1326
- 195 Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B. et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science* **332**, 1317–1322
- 196 Peng, T., Golub, T. R. and Sabatini, D. M. (2002) The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. *Mol. Cell. Biol.* **22**, 5575–5584
- 197 Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K. and Puigserver, P. (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1 α transcriptional complex. *Nature* **450**, 736–740
- 198 Duvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S. et al. (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol. Cell.* **39**, 171–183
- 199 Hannan, K. M., Brandenburger, Y., Jenkins, A., Sharkey, K., Cavanaugh, A., Rothblum, L., Moss, T., Poortinga, G., McArthur, G. A., Pearson, R. B. and Hannan, R. D. (2003) mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxyterminal activation domain of the nucleolar transcription factor UBF. *Mol. Cell. Biol.* **23**, 8862–8877
- 200 de Groot, R. P., Ballou, L. M. and Sassone-Corsi, P. (1994) Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. *Cell* **79**, 81–91
- 201 Yamnik, R. L., Digilova, A., Davis, D. C., Brodt, Z. N., Murphy, C. J. and Holz, M. K. (2009) S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation. *J. Biol. Chem.* **284**, 6361–6369
- 202 Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M. and Manning, B. D. (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. *Mol. Cell* **24**, 185–197
- 203 Carnevalli, L. S., Masuda, K., Frigerio, F., Le Bacquer, O., Um, S. H., Gandin, V., Topisirovic, I., Sonenberg, N., Thomas, G. and Kozma, S. C. (2010) S6K1 plays a critical role in early adipocyte differentiation. *Dev. Cell* **18**, 763–774
- 204 Yeh, W. C., Bierer, B. E. and McKnight, S. L. (1995) Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 11086–11090
- 205 Zhang, H. H., Huang, J., Duvel, K., Boback, B., Wu, S., Squillace, R. M., Wu, C. L. and Manning, B. D. (2009) Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. *PLoS ONE* **4**, e6189
- 206 Harada, H., Andersen, J. S., Mann, M., Terada, N. and Korsmeyer, S. J. (2001) p70 S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 9666–9670
- 207 Lai, K. P., Leong, W. F., Chau, J. F., Jia, D., Zeng, L., Liu, H., He, L., Hao, A., Zhang, H., Meek, D. et al. (2010) S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. *EMBO J.* **29**, 2994–3006
- 208 Narayanan, U., Nalavadi, V., Nakamoto, M., Thomas, G., Ceman, S., Bassell, G. J. and Warren, S. T. (2008) S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. *J. Biol. Chem.* **283**, 18478–18482
- 209 Hoeffer, C. A. and Klann, E. (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. *Trends Neurosci.* **33**, 67–75
- 210 Aguilar, V., Alliouachene, S., Sotiropoulos, A., Sobering, A., Athea, Y., Djouadi, F., Miroux, S., Thiaudiere, E., Foret, M., Viollet, B. et al. (2007) S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. *Cell Metab.* **5**, 476–487
- 211 Ruvinsky, I., Katz, M., Drazan, A., Gielchinsky, Y., Saada, A., Freedman, N., Mishani, E., Zimmerman, G., Kasir, J. and Meyuhav, O. (2009) Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. *PLoS ONE* **4**, e5618
- 212 Chakrabarti, P., English, T., Shi, J., Smas, C. M. and Kandror, K. V. (2010) Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes* **59**, 775–781
- 213 Soliman, G. A., Acosta-Jaquez, H. A. and Fingar, D. C. (2010) mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. *Lipids* **45**, 1089–1100
- 214 Blouet, C., Ono, H. and Schwartz, G. J. (2008) Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. *Cell Metab.* **8**, 459–467
- 215 Cota, D., Proulx, K., Smith, K. A., Kozma, S. C., Thomas, G., Woods, S. C. and Seeley, R. J. (2006) Hypothalamic mTOR signaling regulates food intake. *Science* **312**, 927–930
- 216 Myers, Jr, M. G., Leibel, R. L., Seeley, R. J. and Schwartz, M. W. (2010) Obesity and leptin resistance: distinguishing cause from effect. *Trends Endocrinol. Metab.* **21**, 643–651
- 217 Mori, H., Inoki, K., Munzberg, H., Opland, D., Faouzi, M., Villanueva, E. C., Ikenoue, T., Kwiatkowski, D., MacDougald, O. A., Myers, Jr, M. G. and Guan, K. L. (2009) Critical role for hypothalamic mTOR activity in energy balance. *Cell Metab.* **9**, 362–374
- 218 Choo, A. Y. and Blenis, J. (2009) Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. *Cell Cycle* **8**, 567–572
- 219 Barlund, M., Monni, O., Kononen, J., Cornelison, R., Torhorst, J., Sauter, G., Kallioniemi, O.-P. and Kallioniemi, A. (2000) Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. *Cancer Res.* **60**, 5340–5344
- 220 Nardella, C., Lunardi, A., Fedele, G., Clohessy, J. G., Alimonti, A., Kozma, S. C., Thomas, G., Loda, M. and Pandolfi, P. P. (2011) Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. *Cancer Res.* **71**, 3669–3675
- 221 Shioi, T., McMullen, J. R., Tarnavski, O., Converso, K., Sherwood, M. C., Manning, W. J. and Izumo, S. (2003) Rapamycin attenuates load-induced cardiac hypertrophy in mice. *Circulation* **107**, 1664–1670
- 222 Chen, J. K., Chen, J., Neilson, E. G. and Harris, R. C. (2005) Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. *J. Am. Soc. Nephrol.* **16**, 1384–1391
- 223 Chen, J. K., Chen, J., Thomas, G., Kozma, S. C. and Harris, R. C. (2009) S6 kinase 1 knock-out inhibits uninephrectomy- or diabetes-induced renal hypertrophy. *Am. J. Physiol. Renal Physiol.* **297**, F585–F593
- 224 McMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Dorfman, A. L., Longnus, S., Pende, M., Martin, K. A., Blenis, J. et al. (2004) Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor phosphoinositide 3-kinase-induced cardiac hypertrophy. *Mol. Cell. Biol.* **24**, 6231–6240

- 225 Antion, M. D., Merhav, M., Hoeffler, C. A., Reis, G., Kozma, S. C., Thomas, G., Schuman, E. M., Rosenblum, K. and Klann, E. (2008) Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. *Learn. Mem.* **15**, 29–38
- 226 Fontana, L., Partridge, L. and Longo, V. D. (2010) Extending healthy life span—from yeast to humans. *Science* **328**, 321–326
- 227 Yang, Z. and Klionsky, D. J. (2010) Eaten alive: a history of macroautophagy. *Nat. Cell Biol.* **12**, 814–822
- 228 Madeo, F., Tavernarakis, N. and Kroemer, G. (2010) Can autophagy promote longevity? *Nat. Cell Biol.* **12**, 842–846
- 229 Yang, Z. and Klionsky, D. J. (2010) Mammalian autophagy: core molecular machinery and signaling regulation. *Curr. Opin. Cell Biol.* **22**, 124–131
- 230 Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S. et al. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* **460**, 392–395
- 231 Selman, C., Tullet, J. M., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadan, F. et al. (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science* **326**, 140–144
- 232 Pearce, L. R., Alton, G. R., Richter, D. T., Kath, J. C., Lingardo, L., Chapman, J., Hwang, C. and Alessi, D. R. (2010) Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). *Biochem. J.* **431**, 245–255
- 233 Jung, C. H., Ro, S. H., Cao, J., Otto, N. M. and Kim, D. H. (2010) mTOR regulation of autophagy. *FEBS Lett.* **584**, 1287–1295

Received 19 May 2011/4 August 2011; accepted 5 August 2011

Published on the Internet 14 December 2011, doi:10.1042/BJ20110892